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ABSTRACT 
Understanding the mechanisms of enzymes is crucial for our understanding of their role in biology 
and for designing methods to perturb or harness their activities for medical treatments, industrial 
processes, or biological engineering.  One aspect of enzymes that makes them difficult to fully 
understand is that they are in constant motion, and these motions and the conformations adopted 
throughout these transitions often play a role in their function. 
Traditionally, it has been difficult to isolate a protein in a particular conformation to determine what 
role each form plays in the reaction or biology of that enzyme.  A new technology, computational 
protein design, makes the isolation of various conformations possible, and therefore is an extremely 
powerful tool in enabling a fuller understanding of the role a protein conformation plays in various 
biological processes. 
One such protein that undergoes large structural shifts during different activities is human type II 
transglutaminase (TG2).  TG2 is an enzyme that exists in two dramatically different conformational 
states: (1) an open, extended form, which is adopted upon the binding of calcium, and (2) a closed, 
compact form, which is adopted upon the binding of GTP or GDP.  TG2 possess two separate 
active sites, each with a radically different activity.  This open, calcium-bound form of TG2 is 
believed to act as a transglutaminse, where it catalyzes the formation of an isopeptide bond between 
the sidechain of a peptide-bound glutamine and a primary amine.  The closed, GTP-bound 
conformation is believed to act as a GTPase.  TG2 is also implicated in a variety of biological and 
pathological processes. 
To better understand the effects of TG2’s conformations on its activities and pathological processes, 
we set out to design variants of TG2 isolated in either the closed or open conformations.  We were 
able to design open-locked and closed-biased TG2 variants, and use these designs to unseat the 
current understanding of the activities and their concurrent conformations of TG2 and explore each 
conformation’s role in celiac disease models.  This work also enabled us to help explain older 
confusing results in regards to this enzyme and its activities.  The new model for TG2 activity has 
immense implications for our understanding of its functional capabilities in various environments, 
and for our ability to understand which conformations need to be inhibited in the design of new 
drugs for diseases in which TG2’s activities are believed to elicit pathological effects. 
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C h a p t e r  1  
INTRODUCTION 
 
Proteins are dynamic 
One of the major strengths of protein crystallography is that it allows us to view protein structures 
with atomic detail, and from this structural information deduce functional relevance and biological 
mechanisms.  However, these static images can give the viewer the wrong impression: proteins are 
in constant motion, sampling an array of conformations, with some movements miniscule, others 
dramatic.  These small conformational vibrations or radical reorganizations can be critical for 
biological function or sometimes enormously detrimental.  For example, hemoglobin, responsible 
for delivering oxygen to tissues, undergoes a conformational change upon the binding of oxygen to 
the first of its four subunits that translates to an increase in oxygen affinity in the remaining subunits 
[1].  Conversely, misfolded proteins called prions are infectious agents that can cause disease by 
acting as a conformational template for existing proteins, effecting a cascade where they induce the 
normally folded proteins to adopt the prion’s misfolded and disease-associated state [2]. 
Therefore, a full understanding of the dynamics of a protein is essential for teasing out its 
mechanism of action, and if necessary, how to perturb any unwanted behavior.   
 
Human tissue transglutaminase undergoes a very large conformational change 
One such enzyme whose biological activity is intimately intertwined with its conformational 
inclinations is human tissue transglutaminase, also known as human type II transglutaminase (TG2).  
TG2 consists of four domains: an N-terminal β-sandwich, a core, and two β-barrel domains (Figure 
1-1).  TG2 exists in two distinct conformations, closed and open, and each conformation was 
believed to catalyze a separate reaction; the closed conformation was believed to act as a GTPase, 
while the open was believed to act as the transglutaminase [3-5].   
In the closed conformation, the transglutaminase active site is sequestered in a grove between the 
core and the interface of the β-barrel domains, which was believed to prevent its activity in the 
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closed conformation (Figures 1-2, 1-3).  The GTPase site is formed on the opposite face of the 
protein at the core-β1-barrel interface [5]. TG2 assumes the closed conformation upon GTP 
binding, and therefore this is the conformation that was assumed to be adopted during the GTPase 
reaction.  The closed conformation is also the preferred conformation.   
In the extended, open conformation, which occurs upon calcium binding and exposes the 
transglutaminase active site residues at the core just above the β1-barrel, TG2 is believed to catalyze 
an acyltransferase reaction relatively non-specifically.  This results in the formation of an amide 
bond between a peptide-bound γ-carboxamide of glutamine and the ε-amino group of lysine or 
another primary amine (Figure 1-4) [6].  The first step of this reaction occurs when a thiol residue 
(C227 - part of a stereotypical catalytic triad) attacks a gluamine’s carboxamide, releasing ammonia 
and forming a covalently-linked intermediate (Figure 1-5).  A cross link is formed when a lysine 
sidechain or another primary amine attacks this intermediate.  The resulting γ-glutamyl-ε-lysine[Nε-
(γ-L-glutamyl)-L-lysine] (GGEL) isopeptide linkage can occur between glutamine and lysine 
residues in different peptides, stabilizing these polymers.  Alternatively, TG2 can proceed only 
halfway through the reaction, deamidating a glutamine residue to form a glutamate (Figure 1-4) [6].  
In the open conformation, the GTPase active site is torn in half as the residues making up this active 
site reside on both the core and the β1-barrel.  Therefore, upon assuming the open conformation, 
TG2 was believed to be incapable of acting as a GTPase (Figure 1-6) [3]. 
The transition from closed to open predominately involves the movement of random coils.  
Therefore, most of TG2’s secondary structural elements remain in their original conformations in 
both the open and closed structures, with one notable exception: residues 309 through 319.  These 
residues make up the hinge of TG2 and undergo a dramatic secondary structural change upon the 
shift from open to closed.  They form a β-strand in the closed conformation and an α-helix in the 
open conformation (Figure 1-7) [3, 5].   
 
TG2 is regulated by a number of effectors 
TG2 is present in most mammalian tissues, and exists both intracellularly and extracellularly [7, 8].  
Therefore, it is essential that its activities be tightly regulated, especially given the promiscuity of 
the transglutaminase activity (see Figure 1-8) [9, 10].  
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TG2’s GTPase activity is inhibited by Ca2+ [11] with an estimated IC50 ranging from 300 nM to 6 
µM [12, 13], and GTP inhibits the transglutaminase activity with a dissociation constant of 1.6 µM 
[14].  TG2 binds six Ca2+ ions with an apparent overall dissociation constant of 90 µM [11, 15]. The 
GTPase reaction has a Km of approximately 130 µM [4, 16].  The concentration of Ca2+ required for 
in vivo transglutaminase activity, however, is less well defined.  In permeabilized cells, 10-100 µM 
Ca2+ is required for measurable TG2 activity.   
These results led to the belief that TG2 is a latent enzyme with respect to transglutaminase activity 
under normal intracellular conditions [17], where Ca2+ concentrations are typically below 1µM and 
GTP is readily available [9].  However, later studies demonstrated that TG2 could be activated in 
situ by physiological increases in calcium concentration to approximately the nanomolar range, 
suggesting that intracellular factors may increase TG2’s calcium sensitivity [18]. 
Extracellularly, where the concentration of Ca2+ ions is high and GTP is low, a more amenable 
environment exists for the transglutaminase activity of TG2.  However, TG2 remains largely 
inactive as a transglutaminase extracellularly under normal conditions due to inactivation via 
oxidation [19].  Due to the high redox potential of the extracellular matrix, a reversible disulfide 
bridge forms between C371 and C370, which alters the backbone of TG2 and induces the adoption 
of the open conformation, which, surprisingly, inactivates TG2 by a mechanism that is not yet clear 
[20, 21]. 
The mechanism by which the extracellular transglutaminase activity of TG2 is activated is still 
under investigation, but known activators include the protein cofactor thioredoxin-1 [21], 
interferon-γ [21, 22], and cellular stresses like tissue injury [19, 23]. 
 
       
How are these activities and conformations biologically relevant? 
TG2 is found ubiquitously in mammalian tissues (hence its name), including the liver, brain, 
intestine, and erythrocytes [24, 25].  TG2 is located both intracellularly and extracellularly [8].  
Though primarily in the cytosol [26], TG2 can be found in the extracellular matrix [27], associated 
with the plasma membrane [4, 28], in the nucleus [29-31], and in mitochondria [32, 33].   
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TG2’s diverse locations and activates have led it to be implicated in a wide variety of physiological 
processes.  For example, extracellular TG2’s transglutmainase activity plays a role in wound 
healing [19, 34], while intracellular TG2 acting as a GTPase has been shown to be the functional α-
subunit of a G-protein involved with α1 adrenergic receptor signaling [4], as well as with other 
receptor types [35, 36].  However, the biological importance of TG2 as a G-protein is still being 
determined [37, 38].  TG2 has also been shown to both promote apoptosis and promote cell 
survival, depending on the circumstances.  TG2 is involved in cell adhesion [39, 40], matrix 
stabilization [41-43], cell proliferation and migration [10, 44], neuronal growth and regeneration 
[45-47], and as a transcriptional regulator of a myriad of processes involving stress induced nuclear 
localization [48-57]. 
 
Tissue transglutaminase is a unique member of a large protein family 
The transglutaminase family consists of 9 members: TG1 through TG7, factor XIII, and band 4.2 
[58, 59].  All but band 4.2 can act as transglutaminases, and these all require Ca2+ binding for this 
activity [58]. As mentioned above, TG2 is the most widely expressed of all the transglutaminases, 
and is found in almost every tissue of the body [9, 10].  The other transglutaminases are more 
specifically expressed, for instance, TG1, TG3, and TG5 are expressed in keratinocytes and/or hair 
follicles and are involved in differentiation [60-66]. TG4 is localized in the prostate gland and its 
role in human biology is not yet totally understood [67].  Factor XIII is found in plasma, platlets, 
monocytes, and macrophages and is involved in functions such as fibrin stabilization, wound 
healing, and angiogenesis [68-76]. 
TG1 through TG7 and band 4.2 exist as monomers [66, 68, 77].  In the plasma, factor XIII exists as 
a tetramer with two potentially active FXIII-A subunits and two inhibitory/carrier FXIII-B subunits 
(FXIII-A2B2) [68].  In the cytoplasm of platelets and monocytes, factor XIII is a dimer (FXIII-A2) 
[68].  
Crystal structures have been determined for only three of these transglutaminases: factor XIII-A2, 
TG2, and TG3 [3, 5, 78-80].  TG2 is the only transglutaminase confirmed to act as a GTPase and 
the only transglutaminase crystallographically shown to adopt the elongated open conformation.  As 
mentioned above, all three of these transglutaminases require Ca2+ binding for activation [58].  
Although TG2 adopts an open conformation upon Ca2+ binding and has been shown to bind six Ca2+ 
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ions, no Ca2+ was found bound to the open crystal structure, which was achieved by covalent 
inhibition by a peptide substrate in the transglutaminase active site [3, 11].   
Factor XIII is activated by thrombin and by the binding of a single Ca2+ ion [81, 82].  Thrombin 
cleaves off an N-terminal peptide by hydrolyzing the R37-G38 peptide bond that, in addition to the 
binding of calcium, causes the inhibitory FXIII-B subunits to dissociate from the complex, resulting 
in the active dimer FXIII-A2* [83-86].  The structure adopted by the active form of factor XIII, 
FXIII-A2*, is still being debated.  Hydrogen deuterium exchange experiments and chemical 
modification of side chains studies have suggested conformational changes occur when the enzyme 
transitions from inactive FXIII-A2 to active FXIII-A2* [87-89].  However, the crystal structure of 
thrombin activated and Ca2+-bound FXIII-A2 still adopted the closed conformation and did not 
appear significantly different from the non-activated form of FXIII-A2 [90].  This implies that any 
conformational changes in FXIII-A2 may be fleeting and unstable.   
In order to be activated, TG3 binds three Ca2+ ions [80] and undergoes a cleavage event in the 
region equivalent to the hinge region in TG2, resulting in two globular domains that remain 
associated with each other in the closed conformation: a 50 kDa amino terminus with the catalytic 
site and a 27 kDa carboxy terminus [66, 91].  Crystal structures of TG3 in its active conformation 
bound to 3 Ca2+ ions have been solved [80, 92], as well as structures for the inactive form of the 
enzyme [80].  Surprisingly, the active and calcium-bound form of TG3 remains in the closed 
conformation, but activation causes a loop consisting of residues 320 to 325 to move and open a 
cavity through the enzyme towards the active site residues, although further rearrangements are 
believed to be necessary to accommodate substrates [93].  TG3 is not believed to adopt an open, 
elongated conformation similar to that of TG2. 
 
TG2 is the most nonspecific recognizer of glutamine donor substrates of all transglutaminases 
In addition to being the only transglutaminase definitively shown to adopt an open, elongated 
conformation, TG2 is also the least discriminating in its choices of transglutaminase substrates.  
TRANSDAB is a database of all known transglutaminase substrate proteins and interaction partners 
[94].  TG2 has by far the largest number of known substrate proteins, with the current count being 
155, and has long been known to be extremely nonspecific [9, 10].  Factor XIII-A is much more 
specific in its recognition of glutamine residues than TG2 [94] and has a much smaller amount of 
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known substrates at 28, although the two glutamine donors fibrin and α2-PI are significantly better 
substrates than the others listed [68, 95, 96].  TG3 acts on 16 known substrates and is considered 
highly specific [92].  The other transglutaminases are also extrememly specific: TG1 has 14 known 
substrates, TG4 has 3, and TG5 has 4.  
It is interesting to note that among TG2, factor XIII, and TG3, substrate promiscuity increases with 
observed increasing conformational flexibility upon the binding of Ca2+.  TG2 is the most 
promiscuous and adopts a fully elongated conformation upon calcium binding.  Factor XIII has 
been shown to undergo conformational changes, although not observed in the crystal structure 
bound to calcium, and has much stricter substrate preferences.  TG3, which has been shown to 
undergo a flexing to open a channel to the active site and remain in the closed conformation when 
bound to calcium, exhibits the highest specificity of the three.    
 
Truncation studies of TG2 have produced confusing results as to which domains are necessary and 
sufficient to preform TG2’s activities 
As mentioned above and as shown in Figure 1-3, the crystal structure of TG2 bound to GDP 
revealed that the GTPase active site comprises residues from the core domain and the β-barrel 1 
domain [5].  This result is surprising considering data obtained from two deletion studies.  A 
domain-deletion study found that the core domain alone exhibited a 50% increase in GTPase 
activity when compared to the full-length protein, while a variant with the N-terminal β-sandwich 
and the core, but lacking both β-barrel domains, showed no significant difference in activity relative 
to full-length TG2 [97].  A second study using successive C-terminal deletion analysis to attempt to 
pinpoint the GTP binding site found that deleting off the two β-barrel domains resulted in a 34-fold 
increase in GTPase activity relative to WT [98].  All of these truncated variants of TG2 lacked all 
but two (K173 and F174) of the GTPase active site residues later identified by X-ray 
crystallography (Figure 1-3). 
The same two papers investigated these deletions’ effects on the transglutaminase activity.  The 
domain-deletion study found that the loss of the two β-barrel domains caused a 30% loss in activity 
relative to full-length TG2, while the core domain alone lacked any transglutaminase activity [97].  
The successive C-terminal deletion analysis found that the first variant with the deletion of β-barrel 
1 and half of β-barrel 2 and a second variant with the deletion of both β-barrels resulted in a 95-99% 
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loss in transglutaminase activity relative to full-length protein [98].  Again, this is a surprising result 
considering that all the active site residues involved in catalysis and substrate and calcium binding 
identified biochemically and in the open conformation crystal structure reside in the core and were 
neither deleted in any of these truncation variants, nor do they directly interact with any of those 
residues deleted [3, 11]. 
 
The transglutaminase activity of TG2 plays a critical role in celiac disease 
Celiac disease (CD) is an autoimmune condition affecting the small intestine, and is triggered in 
genetically predisposed individuals by the ingestion of gluten – proteins present in wheat and other 
grains.  In CD, antibodies attack the small intestinal lining, causing the formation of lesions 
characterized by increased epithelial cell proliferation and decreased differentiation, as well as the 
infiltration of T cells into the mucosa [99, 100].  These cellular events lead to the classic symptoms 
of villious atrophy and crypt hyperplasia, which cause diarrhea and impair the patient’s ability to 
absorb nutrients [101, 102].  CD can also present extraintestinally, in symptoms including 
osteoporosis, dermatitis herpetiformis, and neurological disorders, such as gluten ataxia [103].  
Gluten is an insoluble heterogeneous mixture of storage proteins known as gliadins and glutenins, 
both of which contain repetitive sequences enriched in proline (Pro; 15%) and glutamine (Gln; 
35%).  These residues render the gluten resistant to proteases, and the resulting 30-40 residue-length 
peptides remain intact when they are released into the gut lumen [104, 105].   
At this point in celiac disease, tissue transglutaminase plays its first known role.  Intestinal TG2 
deamidates the gluten peptides at specific Gln residues, increasing their affinity for the mutant 
histocompatibility class II molecule HLA-DQ2 (present in 90% of patients), or HLA-DQ8 (10% of 
patients), on the surface of antigen-presenting cells (APCs) [106, 107].  The peptide is then 
presented to a DQ2/8-restricted CD4+ T cell, which elicits the T cell’s proliferation and the 
deleterious immune activation characterizing CD [108-110]. 
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CD is characterized by anti-TG2 antibodies  
TG2 itself is the primary autoanitgen in celiac disease [111].   Anti-TG2 antibodies produced by 
celiac patients are highly specific and detection of their presence is the primary means of diagnosis 
[111-114].  Upon the ingestion of gluten in an afflicted individual, anti-TG2 antibodies are secreted 
in the small intestinal mucosa [115], accumulating immediately below the small-bowel epithelial 
membrane around mucosal blood vessels [116, 117].  Here, the autoantibodies bind extracellular 
TG2 on fibroblasts on the small intestine’s basement membrane [112, 116, 118].  Interestingly, in 
this same region, the subepithelial layer of the jejunal mucosa, studies have demonstrated an 
increase in TG2 expression and transglutaminase activity in the celiac patient [119, 120].  On a 
related note, TG3 has also been identified as the autoantigen of dermatitis herpetiformis, a blistering 
skin disease associated with celiac disease as mentioned above [65].   
 
CD anti-TG2 autoantibodies affect CD symptoms and TG2 transglutaminase activity 
Surprisingly, these anti-TG2 autoantibodies were found not to ameliorate symptoms in celiac 
patients, but to affect pathogenic symptoms.  Celiac autoantibodies have been shown to induce 
proliferation and inhibit differentiation of epithelial cells [121], possibly contributing to the 
development of crypt hyperplasia, which is characterized by precisely that. Anti-TG2 celiac 
autoantibodies have also been shown to induce apoptosis both in neuronal cells and trophoblasts, 
possibly contributing to the neurological and pregnancy complications observed in CD [122, 123]. 
Celiac autoantibodies also enhance lymphocyte binding to the endothelium and transendothelial 
migration, accompanied by an up-regulation in the lymphocyte adhesion molecule E-selectin [124], 
which is interesting in light of reports that in untreated celiac disease, lymphocyte adhesion 
molecules including E-selectin are up-regulated in the intestinal mucosal, possibly contributing to 
lymphocyte migration into the lamina propria from the endothelial barrier [125-127].  Total celiac 
IgA and anti-TG2 celiac IgA have been reported to inhibit angiogenesis and increase vascular 
permeability, whereas commercially available anti-TG2 antibody, CUB7402, or non-celiac IgA did 
not [124, 128-132], possibly contributing to the disorganization reported in the vascular architecture 
of the CD lesion [133].   
In angiogenesis, new blood vessels are formed from old ones, and processes playing a key role, 
such as matrix stabilization, are carefully regulated [8].  TG2 has been implicated in numerous 
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studies to play a role in matrix stabilization relevant to angiogenesis, promoting angiogenesis during 
wound healing [134] and inhibiting it during tumor formation by increasing the accumulation of 
extracellular matrix proteins [135, 136], presumably because angiogenesis generally requires 
localized destabilization of the extracellular matrix [137].  In addition, TG2 expression is 
downregulated in endothelial cells during capillary morphogenesis [138].   
Interestingly, it was reported that the anti-angiogenesis effects induced by celiac disease anti-TG2 
autoantibodies, such as increased endothelial cell macromolecule permeability and tubule length, 
could be reversed upon the addition of the TG2 transglutaminase inhibitor R281 [124, 129].  The 
above findings led to the hypothesis that the anti-TG2 autoantibodies could perhaps be activating 
the transglutaminase activity of TG2, and that this activation could lead to further disease 
progression by increasing TG2’s deamidation of gluten. Initial studies using liquid phase assays 
showed that celiac anti-TG2 autoantibodies had a moderate inhibitory effect on transglutaminase 
activity [139-141].  More recent studies either more closely mimicking in vivo conditions [142], or 
in situ with live endothelial cells [124, 129] demonstrated that celiac patient autoantibodies or 
celiac-derived monoclonal anti-TG2 antibodies actually enhanced transglutaminase activity, while 
commercially available or non-CD IgA did not.  In the first study [142], this activation was lost 
once the celiac patient removed gluten from their diet.  The latter two studies [124, 129] showed 
that this activation was lost upon the addition of transglutaminase inhibitors.   
  
 
 
Celiac anti-TG2 autoantibodies recognize a conformational epitope consisting of residues from 
three domains 
Early attempts to identify epitopes recognized by CD autoantibodies on TG2 consisted of 
fragmentation studies.  One such study found that both the N- and C-terminal domains of TG2 were 
important for the binding celiac patient antibodies [143].  A second, similar study found that both 
the N- and C-termini harbored recognized epitopes, but that the core needed to also be present with 
either terminus in order for binding.  The core itself was not found to be sufficient [144].  A third 
study found that the core and N-terminus were important for recognition [145].  Fragmentation 
studies are not ideal, however, since the epitopes recognized by anti-TG2 celiac antibodies are 
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known to be conformationally dependent, indicated by their inability to bind linearized TG2 
peptides in phage display [146] or there decreased ability to bind in Western blot or paraffin-
embedded tissues [147]. 
Recently, a group working on determining the Ca2+ binding sites on TG2 noticed that one of their 
calcium binging-site knock-outs destroyed celiac IgA’s ability to bind TG2.  However, the presence 
of calcium or GDP had no effect on celiac IgA’s ability to bind wild-type TG2.  After further 
investigation, they were able to define a single TG2 epitope recognized by IgA from 18 different 
celiac patients that resided close to this calcium binding site.  This epitope consists of residues from 
the N- and C-termini and the core, in agreement with the fragmentation studies mentioned above, 
and is only completely assembled in the closed conformation [148].  This led them to hypothesize 
that the binding of celiac antibodies to TG2 may stabilize the closed conformation, and by doing so 
confer the gain in catalytic activity observed in the above-mentioned studies.  However, the idea 
that the closed form of TG2 is the more active is contrary to the long-held view that the open, 
extended conformation of TG2 was the transglutaminase active form.   
 
Conformational protein design is an excellent tool for studying conformational roles in biology 
The multifunctional nature of TG2 complicates our ability to determine its role in cell physiology 
and pathology.  Firstly, it is desirable to confirm or disprove assumptions about TG2’s 
conformations’ affects on its activities made based on crystal structures.  In addition, it would be 
useful to isolate both of TG2’s activities from each other in order to pinpoint which activities and 
conformations of TG2 contribute to various biological processes. Unfortunately, traditional methods 
used to do this are not tractable for TG2.  Inhibition is a very common method used to selectively 
block enzymatic activity, but small molecule inhibitors can have undesirable secondary effects.  For 
example, transglutaminase inhibitors have been known to force the adoption of the open 
conformation of the enzyme [3, 20].  Active site mutational knock-outs are undesirable in the case 
of TG2 because (1) they assume our model for TG2 activities and their corresponding 
conformations is correct, and (2) mutations to the catalytic cysteine of the transglutaminase active 
site (C277) are also known to cause TG2 to adopt the open conformation [149-151]. 
Using computational protein design (CPD) to design variants of TG2 that isolate each conformation 
would be one way to get around many of these challenges.  The Mayo lab has already demonstrated 
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CPD’s ability to preferentially stabilize a protein in two distinct conformation states [152].  In this 
work, CPD was used to stabilize the integrin I domain in either the open or closed conformation.  
Experimental results showed the open-form variants to be much more active than the WT integrin I, 
whereas the closed-form variants exhibited no activity, demonstrating that the open conformation is 
the physiologically relevant conformation for activation by ligand binding. 
In CPD, the design algorithm samples amino acid types and conformations at the designated 
positions in each fold simultaneously.  Pairwise interaction energies between amino acid sidechains 
and between sidechains and backbone are calculated using a molecular mechanics force field with 
terms for van der Waals interactions, atomic solvation, electrostatics, and hydrogen bonding [153-
157].  An overall score for each sequence in the context of a particular fold is calculated from these 
interaction energies, and the sequence with the minimum energy is found using a sequence 
optimization algorithm [158-160].   
The goal of this thesis was to use CPD to construct variants of TG2 locked into a single 
conformational state, i.e., stabilized in either the closed form (closed-locked) or the open form 
(open-locked), and then use these designs to gain insight into the biology of this enzyme. 
If the model depicted in Figure 1-8 were correct, a closed-locked TG2 variant would eliminate 
transglutaminase activity without the use of a small molecule inhibitor that may have unwanted side 
effects.  In addition, a closed-lock design should maintain GTPase activity, isolating it from the 
transglutaminase activity and the open conformation.  A closed-locked design would allow us to 
test the assumption that the closed conformation is inactive as a transglutaminase and could be used 
to validate the role of the GTPase reaction alone in physiology and disease. 
An open-locked TG2 variant would allow us to test the hypothesis that the open form of the enzyme 
is the transglutaminase active/GTPase inactive form.  If this hypothesis is correct, the open-locked 
version of the enzyme should be constitutively active with respect to transglutaminase activity and 
should exhibit no GTPase activity.  Again, an open-locked TG2 could then be used to investigate 
the role of the transglutaminase reaction in biology separate from the GTPase activity.  
Additionally, in order to achieve the crystal structure for the open form of the enzyme, an inhibitor 
was necessary [3].  An open-locked form of the enzyme could potentially be used to crystallize the 
apo form of the enzyme. 
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Given that (1) other TG2’s seem to be active in a more closed form, (2) truncation studies have 
shown that the β-barrels were unnecessary for GTPase activity and necessary for transglutaminase 
activity, and (3) celiac anti-TG2 autoantibodies can increase transglutaminase activity and seem to 
bind a closed form of the enzyme, the real possibility existed that the long-held model for the 
activities and conformations of TG2 was incorrect.  Designing such open and closed-locked TG2s 
enabled us to investigate this hypothesis.   
Chapter 2 of this thesis describes the testing of the existing model for TG2’s activities, activation, 
inhibition, and corresponding conformation by the design and characterization of open-locked and 
closed-biased variants of TG2.  Chapter 3 investigates if conformationally distinct forms of TG2 
with differing levels of transglutaminase activity can elicit differing effects in cell culture, and 
therefore attempts to further investigate the hypothesis that the stabilization of the closed 
conformation and the resulting increase in transglutmainase activity of TG2 led to pathogenic 
effects observed in CD.  Appendix A details the active site saturation mutagenesis of a designed 
Kemp elimination enzyme from work previously done in our group in an attempt to improve its 
activity and to further optimize our design parameters.  We set out to accomplish this so that the 
predictions made by our computational methods better match that which is observed in vitro and 
therefore improve our model, furthering our long term goal of designing de novo enzymes with 
kcat/Km values closer to those found in nature. Appendix B reports initial work of the expression of 
Ebola Glycoprotein 1,2 for use in antiviral design.  
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Tables and Figures 
 
Figure 1-1.  Human tissue transglutaminase consists of four domains: (1) the N-terminal β-
sandwich (blue), (2) the core (green), (3) β-barrel 1 (yellow), (4) and β-barrel 2 [32].  The hinge 
region is shown in cyan [5].   
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Figure 1-2.  TG2 adopts two conformational states.  The closed state of TG2 (left) occurs upon GTP 
binding.  The open conformation (right) exposed the transglutaminase active site and occurs upon 
calcium binding.  The closed structure shows GDP bound to the GTPase active site [5] and the open 
structure shows the covalently-bound peptide inhibitor Ac-P(DON)LPF-NH2 bound in the 
transglutaminase site [3].  
  
  
15 
 
 
Figure 1-3.  A close up of the GTPase active site of TG2 in the closed conformation, with active site 
residues pictured in green when from the core domain and yellow when from β-barrel 1.  GDP s 
pictured in salmon [5]. 
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Figure 1-4.  TG2 catalyzes the Ca2+-dependent formation of an amide bond between the γ-
carboxamide of a glutamine residue on a protein and the ε-amino group of a lysine or another 
primary amine.  Alternatively, covalent substrate-enzyme intermediate can be hydrolyzed by water 
in a deamidation reaction to convert the glutamine to a glutamate.  This reaction is of particular 
interest in celiac disease, in that when TG2 deamidates gluten, it increases gluten’s affinity for the 
mutant histocompatibility class II molecules, resulting in the immune response characteristic of 
celiac disease [106, 107]. 
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Figure 1-5.  The transglutaminase active site of TG2 in the open conformation [3].  C277 is the 
catalytic residue, and is part of the catalytic triad along with D358 and H335.  D358 hydrogen 
bonds to H335, increasing the pKa of the H335, and allowing it to deprotonate C277.  W241 and 
W332 line the catalytic tunnel and stabilize the enzyme-thiol intermediate. 
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Figure 1-6.  In the open conformation, the GTPase active site is torn in half as the residues making 
up this active site reside on both the core and the β1-barrel. Therefore, upon assuming the open 
conformation, TG2 was believed to be incapable of acting as a GTPase [3]. Active site residues 
shown in pink. 
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Figure 1-7.  The hinge region of TG2 (residues 309 through 319) forms a β-stand in the closed 
conformation [5], and an α-helix in the open [3]. 
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Figure 1-8.  Multiple effectors regulate TG2’s activities and conformations.  Ca2+ inhibits GTPase 
activity and drives the adoption of the open conformation [11], while GTP inhibits transglutaminase 
activity and leads to the adoption of the closed conformation [14].  Oxidation of TG2 causes the 
formation of a disulfide bridge between C370 and C371, locking the enzyme in the open 
conformation and inactivating it [20, 21]. 
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C h a p t e r  2  
STABILIZATION OF TISSUE TRANSGLUTAMINASE IN OPEN OR CLOSED 
CONFORMATIONS USING COMPUTATIONAL MULT-STATE PROTEIN DESIGN 
Abstract 
Human type II transglutaminase (TG2) is an enzyme that exists in two dramatically different 
conformational states, and each was believed to have a unique activity.  In the open, extended form, 
adopted upon calcium binding, the transglutaminase active site is exposed, which was believed to 
allow TG2 to catalyze the formation of an isopeptide bond between the sidechain of a peptide-
bound glutamine and a primary amine.  Upon GTP binding to a separate GTPase active site, TG2 
adopts a compact closed conformation, which partially obstructs the transglutaminase active site 
and therefore was believed to only allow for GTPase activity.  TG2 has been linked to celiac 
disease, as well as many other cellular processes, both physiological and pathological.  However, 
the multi-functional nature of TG2 makes it difficult to determine the relevance of each activity and 
conformation separate from each other.  In this project, we used computational multi-state and 
single-state protein design to engineer TG2 variants adopting either the open or closed 
conformation.  These open-locked and closed-biased TG2 variants allowed us to characterize the 
catalytic capabilities of these conformations.  Specifically, our designs allowed us to determine 
three previously unknown characteristics of TG2: (1) the open conformation of TG2 is insufficient 
for transglutaminase activity, and therefore that the Ca2+-dependence of this reaction is derived from 
more than driving conformational change, (2) the closed-biased designs of TG2 have higher 
transglutaminase activity than the open-locked designs, and in some cases, WT, and (3) not only 
can both conformations act as a GTPase, but the open-locked TG2 is significantly more active than 
the WT or closed-biased designs.  These discoveries have important implications for the celiac drug 
design and for understanding the catalytic capabilities and possible effects of TG2 under various 
biological conditions. 
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Introduction 
Human type II transglutaminase [1] is a member of a large family of enzymes that catalyze the 
Ca2+-dependent crosslinking of enzymes [2, 3].  This reaction, known as the transglutaminase or 
transamidation reaction, catalyzes the formation of an isopeptide bond between the sidechain of a 
peptide-bound glutamine and a primary amine from another protein, i.e., a lysine residue [2, 4, 5].  
This cross-linking reaction is used to modulate the strength of various biological structures.  Other 
members of this enzyme family include TG3 and factor XIII, which are involved in differentiation 
in hair follicles and stabilizing fibrin and therefore blood clots, respectively [6-17].  TG2 is 
expressed in most mammalian tissues and is found both intercellularly and extracellularly [18-20] 
and is implicated in a wide variety of biological processes including differentiation and apoptosis 
[21-23], wound healing [24, 25], and neuronal growth and regeneration [26-28]. 
Unlike other transglutaminases, TG2 also acts as a GTPase and has been shown to adopt two 
dramatically different conformational states, each believed to have its own activity [29-31]. TG2 
consists of four domains: (1) the N-terminal β-sandwich, (2) the core domain, (3) β-barrel 1, and (4) 
β-barrel 2.  In the open conformation, these domains are aligned linearly resulting in an elongated 
form of the enzyme [29].  In the closed conformation, β-barrels 1 and 2 fold onto the core domain, 
much like the folding of a jack-knife, resulting in a compact conformation.  Surprisingly, the 
secondary structure of these domains remain relatively unchanged in each conformation, and the 
majority of backbone rearrangement occurs in the region of the protein between the core and β-
barrel 1 [30].  This region largely consists of random coils, save for a motif comprising residues 309 
through 319, known as the hinge.  In the closed form of the enzyme, these residues form a β-strand, 
while in the open conformation they adopt an α-helix. 
In the closed conformation, the transglutaminase active site is wedged into a grove between the core 
and the interface of the β-barrel domains [30].  This was believed to block its activity.  Conversely, 
the GTPase active site is located in the interface between the core and β-barrel 1 that forms in the 
closed conformation on the opposite side of TG2 relative to the transglutaminase active site.  The 
GTPase active site residues were deduced from the closed structure of TG2 bound to GDP [30].  
TG2 assumes the closed conformation upon GTP binding and is the preferred conformation of the 
enzyme.  Intracellularly, TG2 uses this activity to act as an α-subunit of a G-protein [31]. 
The open conformation of TG2 occurs upon the binding of six Ca2+ ions to the core domain [29, 
32].  However, the only crystal structure of the open conformation has no calcium ions bound to it 
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and was achieved through the covalent binding of a peptide inhibitor to the transglutaminase site 
[29].  In the open conformation, the transglutminase active site is exposed at the C-terminal region 
of the core domain of the protein, just above β-barrel 1.  This exposure was believed to result in its 
activation.  All of the transglutaminase active site residues are located on the core, and consist of a 
catalytic triad with an active site cysteine (C277), which attacks a glutamine’s carboxamide, 
releasing ammonia.  If water hydrolyzes the covalent thiol-intermediate, the reaction is a 
deamidiation and the glutamine is converted to a glutamate.  If not, the reaction proceeds as 
described above, and a primary amine attacks the intermediate, resulting in an amide bond [33].  
The GTPase active site is torn in two upon the formation of the open conformation, since the 
GTPase active site residues reside on both the core domain and the β-barrel 1 domain.  Therefore, it 
was long assumed that the open conformation was incapable of acting as a GTPase [29]. 
As alluded to above, Ca2+ inhibits TG2’s GTPase activity [32, 34, 35], and GTP inhibits the 
transglutaminase activity [36].  This inhibition/activation was believed to be due to the large-scale 
conformational change brought about by the binding of calcium or GTP (i.e., the binding of GTP 
causes the closed conformation, and therefore blocks transglutaminase activity and forms the 
GTPase site, and the binding of calcium causes the open conformation, and therefore prevents the 
GTPase activity and exposes the transglutaminase site, leading to its activity).  The 
transglutaminase activity can also be inactivated by the oxidation of TG2, resulting in the formation 
of a disulfide bond between C371 and C370, which causes the enzyme to adopt the open 
conformation [37].  Therefore, under normal conditions intracellularly, where calcium 
concentrations are low and GTP concentrations are higher, TG2 is believed to act as a GTPase, not 
a transglutaminase [38, 39].  Extracellularly, where calcium concentrations are high and GTP low, 
TG2 primarily acts as a transglutaminase or in receptor signaling [40-49].  Due to the high redox 
potential of the extracellular matrix, however, extracellular TG2 may normally be oxidized and can 
be activated by various effectors [25, 37, 50-53], although the mechanism of how this occurs and 
when it is necessary is not yet clear. 
As mentioned above, all transglutaminases require Ca2+ binding for transglutaminase activity [2].  
Of the 9 members of the transglutaminase family, only 3 have been crystallized: TG2, TG3, and 
factor XII [29, 30, 54-56].  All three exhibit strong structural similarity.  However, each of these 
three binds a different number of Ca2+ ions and has a different conformational response to this 
binding.  TG2 binds 6 Ca2+ ions which causes the enzyme to adopt the open conformation, yet the 
open crystal structure had no Ca2+ ions bound [29, 32].  Of the three, only TG2 has been shown to 
adopt this elongated form.  As detailed in Chapter 1, TG2 is also the most promiscuous in regards to 
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its glutamine substrate preferences of the three crystallized transglutaminases [38, 57, 58].  Factor 
XIII binds a single Ca2+ ion [59], and biochemical studies have shown that it may undergo some 
conformational changes during activation [60-62].  However, the crystal structure of thrombin 
activated and Ca2+-bound factor XIII still adopted the closed conformation and did not appear 
significantly different from the non-activated crystal structure [55], implying that such 
conformational changes may be fleeting and unstable.  As discussed in Chapter 1, Factor XIII has 
much stricter substrate preferences than TG2 [10, 58, 63, 64].  However, TG3 is the most discerning 
of all three, having the fewest number of known glutamine substrates [58, 65].  Interestingly, TG3, 
which binds three Ca2+ ions in the crystal structure, undergoes a cleavage event in the hinge region 
of the protein between the core domain and the β-barrel 1 domain, resulting in two globular 
domains that remain associated with each other in the closed conformation, even upon the addition 
of calcium [9, 53, 66].  Therefore, TG3 is not believed to adopt an open conformation.  Substrates 
are believed to be able to access the active site due to two conformational adjustments: (1) calcium 
binding causes a loop to move and open a cavity though the enzyme to the active site and, (2) a 
flexing of the two subunits to accommodate the substrates [67]. 
As discussed in Chapter 1, the role of each domain in TG2’s two activities is not entirely clear due 
to results from truncation studies that conflict with our crystallographic structural understanding of 
the active sites.  For instance, although the GTPase active site comprises residues from the core 
domain and the β-barrel 1 domain, deletion of both β-barrel domains in two separate studies had 
little effect or actually increased GTPase activity relative to the full-length protein [68, 69].  All of 
these truncated variants lacked all but two of the active site residues. 
In addition, these same two studies found that the loss of the β-barrel domains resulted in anywhere 
from a 30% to 99% loss in transgluaminase activity [68, 69], which is puzzling considering that the 
transglutaminase active site residues and the calcium binding sites are all located on the core of the 
protein and do not interact directly with the deleted domains. 
Among its many biological roles, TG2 has also been implicated in pathological events.  In celiac 
disease, for example, TG2 deamidates gluten peptides, the trigger of celiac disease, which increase 
their binding affinity for mutant major histocompatibility complex (MHC) class II molecules, which 
elicits the autoimmune response [70-77].  TG2 is also the primary autoantigen of celiac disease 
[72], and the anti-TG2 autoantibodies that arise in these patients have been shown to be able to elicit 
pathogenic responses all on their own [78-86].  Recently, studies found that autoantibodies against 
TG2 isolated from celiac patients increase TG2 transglutaminase activity and bind a motif that 
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exists in the closed conformation [81, 83, 87, 88], suggesting that the stabilization of this 
conformation leads to the increase in activity, and that this increase in activity may lead to the 
pathogenic effects observed upon the addition of these antibodies to various endothelial cell models.    
If the closed conformation is in fact more active than the open form of the enzyme, it would fly in 
the face of what was for years believed about TG2, but would help account for the results observed 
in the truncation studies and the ability of TG3 and factor XIII to acts as transglutaminases despite 
failing to adopt an open, extended conformation.  Since the promiscuity of these three 
transglutaminases increases with the increasing ability to adopt an open conformation, perhaps such 
opening is more important for allowing more flexibility in the binding of substrates, and less 
essential for transglutaminase activity itself. This calls in to question the hypothesis that calcium’s 
only role is to cause the enzyme to adopt the open conformation and the assumption that this open 
conformation is transglutaminase active of its own merit. 
One way to test the existing model for the activities and their activation, inhibition, and 
corresponding conformations of TG2 would be to engineer conformationally isolated variants of 
TG2.  One method to accomplish such a goal is computational protein design (CPD). 
To selectively stabilize one TG2 conformation over the alternate, a new variation of CPD will be 
used in addition to traditional design methods: multi-state design (MDS) [89, 90].  In MSD, the 
design process considers multiple structural states while determining a protein sequence.  Here, 
possible amino acid sequences are suggested, and the suitability of each sequence is determined by 
calculating an overall energy score acquired from combining the individual energies of rotamer 
optimization calculations performed on each of the considered states [90]. 
During an MSD calculation, each structural state is assigned a single processor in a computer 
cluster.  The job of each processor is to hold the pairwise energy matrix for its assigned state in 
memory, and to use this information to evaluate the energies of candidate sequences in that state 
only.  An additional processor has the job of identifying sequences to be scored, sending these 
sequences to the other processors, collecting the energy results, and determining the overall fitness 
score from this information [71, 90].  MSD can be used to maximize specificity for a target fold by 
stabilizing the desired conformation (positive design) and destabilizing the undesirable 
conformation (negative design).  MSD selects sequences maximizing the transfer of free energy of a 
design from a desired conformation to a group of unwanted conformations [91].  As mentioned 
previously, crystal structures of both the open and closed conformations of TG2 have been solved 
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[29, 30].  MSD can therefore be used to design an open-locked variant of TG2 by stabilizing the 
open conformation (positive design) while destabilizing the closed (negative design), and vice versa 
to design a closed-locked variant. 
Open-locked and closed-locked versions of TG2 would allow us to characterize the catalytic 
capabilities of each conformation, and by understanding the biological conditions in which the 
enzyme resides in in various tissues, predict which activities the enzyme may be catalyzing in these 
scenarios.  Understanding which conformations catalyze which reaction also has important 
implications for drug design; if the closed form of TG2 is catalyzing the deamidation of gluten in 
celiac disease, drugs should be designed to bind this conformation, and not the open.  Therefore, the 
goal of this chapter was to use computational multi-state protein design to engineer and then 
characterize TG2 variants locked in either the open or closed conformation. 
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Methods 
Design of open-locked and closed-biased TG2 
To design variants of TG2 in open-locked and closed-biased conformations, two areas of the protein 
were selected for residue design (Figure 2-1).  These regions were chosen because they show a high 
level of change in environment or structure with the shift between the closed and open forms.  The 
two regions were: (a) the β2-core interface, and (b) the hinge.  In the β2-core interface, residues go 
from being solvent exposed in the open form to buried in the closed.  In the hinge, residues adopt a 
β-strand in the closed form and an α-helix in the open.  Residues located in either active site 
(GTPase or transglutaminase), as well as those known to be involved in Ca2+ binding were excluded 
from all design calculations.  The ResClass tool in the CPD program PHOENIX was used to 
characterize residues’ degrees of solvent exposure [92].  All design calculations were carried out 
using the newly developed CPD program TRIAD and its multi-state design (MSD) capability.  
These calculations determined the optimal sequence (A0) for each conformational state (s).  These 
calculations were carried out in a manner similar to those described in Shimoaka et al. [93], except 
that occlusion-based solvation and the more versatile optimization algorithm FASTER was used 
[90, 93]. 
The MSD algorithm that was used in the design of closed-biased and open-locked TG2 is described 
elsewhere [89, 90].  Two calculations will be run for each of the three design regions: (1) an MSD 
calculation to stabilize the closed conformation of TG2 (closed-locked, PDB ID code: 1KV3), and 
(2) an MSD calculation to stabilize the open form of TG2 (open-locked, PDB ID code: 2Q3Z). In 
these calculations, stabilization of the positive design state (ρ) and destabilization of the negative 
design state (η) will be achieved using the MSD optimization algorithm to determine the sequence 
that minimizes the scoring function σ(A): 
σ(A) = ΔEρ(A) – WΔEη(A)          (1) 
W a weighing factor used to control the relative contributions of ρ-state stabilization versus η-state 
destabilization.  ΔEs(A) is the difference in energy between sequence A in conformation s and the 
optimal sequence A0 for conformation s that was determined by the initial single state design 
calculations: 
ΔEs(A) = Es(A) – Es (A0)             (2) 
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The open-locked TG2 designs were generated by focusing on the β2-core interface and the hinge 
region.  Initial hinge designs were performed in TRIAD using the design residues 309 through 319, 
the rosetta force field, floating residues within 6 Å of the design residues, i.e., their amino acid 
identities were retained, but their side chains could sample alternate conformations, allowing all 
residues at design sites, with “rama,” the secondary structural term varied from 0.4 to 1.6, and the 
weighing factor, W, ranging from 0.05 to 0.5. 
After being informed by these designs for the hinge region, Y315 was selected as the initial design 
residue.  This residue was selected because it favors β-secondary structure over α, while the hinge is 
an α-helix in the open conformation, and because this residue forms a hydrogen bond with the 
backbone of E329 in the closed structure.  To disrupt these interactions, we used the information 
gleaned from our initial designs and rational design and created to mutants: Y315E and Y315A. 
To accommodate the Y315E mutation, MSD calculations were performed exactly as indicated 
above, except rama was defined as 0.8, Y315 was forced to glutamate, L508 was designated a 
design residue and allowed to sample all residues, residues R506, Y528, L566, and V568 were 
designated as design positions or restricted to WT, and W was defined as 0, making this calculation 
a single state design essentially. 
For open-locked designs derived from mutations at the β2-core interface, residues I178, N181, 
S253, I255, G256, E557, V665, N667, and K677 were designated as design positions.  MSD 
calculations were conducted as described above for the initial hinge designs, except rama was 
defined as 0.8, only polar residues were allowed at design positions, and W for the negative design 
was set at 0.05. 
To design closed-biased TG2, residues L312, E314, and F316 were designated as design residues 
and were allowed to sample Val, Ile, Cys, Tyr, Thr, Phe, Trp, His, and Ser, which were chosen 
specifically for their preference for β-secondary structure over α.  MSD calculations were carried 
out as they were for the initial hinge designs to favor the open structure as detailed above, except 
float positions were designated to be all residues within 9 Å of the design positions and the crosseta 
force field was used. 
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Assembly and cloning of human TG2 gene 
Oligonucleotides of approximately 40 nucleotides (nt) in length optimized for expression in 
Escherichia coli (E. coli) were designed for gene assembly of N-terminally His-6 tagged human 
TG2 using the program DNAWorks [94].  The final gene was 1.2 kb in length. 
An assembly reaction was conducted using 2.5 U of KOD Hot Start DNA Polymerase in 1X Buffer 
for KOD Hot Start Polymerase (Novagen), 1.5 mM MgSO4, 0.2 mM of each dNTP, and 0.01 µM of 
each assembly oligonucleotide to a final volume of 50 µL.  The PCR program consisted of 94°C for 
2 min, 25 cycles of 94°C for 30s, 68.2°C for 30s, 68°C for 30s, followed by a final 10 min 
extension period at 68°C.  After an initial run of this program, the program was repeated after the 
reactions were spiked with an additional 2.5 U of KOD Hot Start Polymerase and 0. 01 µmol of 
each dNTP. 
An amplification reaction was then run using 2 U of KOD Hot Start DNA Polymerase in 1X Buffer 
for KOD Hot Start Polymerase (Novagen), 1.5 mM MgSO4, 0.2 mM of each dNTP, 1 µM forward 
and 1 µM reverse amplification primers, and 1 µL of the assembly reaction at a final volume of 50 
µL.  Amplification PCR conditions consisted of 10 min at 94°C, 25 cycles of 94°C for 30s, 65°C for 
30s, 68°C for 120s, and a final 10 min extension at 68°C. 
The assembled TG2 gene was digested using NdeI and BamHI (New England Biolabs) and ligated 
into the E. coli expression vector pET11a (Novagen).    
 
Site-directed mutagenesis 
Mutagenesis primers were designed using Agilent Technologies Quikchange Primer Design tool.  
Mutants of TG2 were generated using a protocol based on the Quikchange Site-Directed 
Mutagenesis Kit (Stratagene). Briefly, 50 ng of template DNA was added to a 50 µl reaction 
mixture containing 5 µl of 10x reaction buffer, 2.5 U of PfuTurbo DNA polymerase, 0.08 mM 
dNTP mix, (Stratagene), and 125 ng of each mutagenesis primer.  PCR was carried out on 
Mastercycler Personal Thermocycler (Eppendorf) with cycling conditions of 95°C for 30 sec, and 
then 18 cycles of 95°C for 30 sec, 52°C for 1 min, and 68°C for 14 min and 40 sec.  Completed 
mutagenesis reactions were then DpnI (New England Biolabs) digested with 40 U of the enzye for 2 
hours at 37°C. 
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Protein expression and purification 
LB/ampicillin starter cultures were inoculated from a glycerol stock of BL-21 (DE3) Gold E. coli 
containing the expression vector pET11a (Novagen) with the gene for the variant of interest and 
grown overnight at 37°C with shaking.  4 mL of starter culture were added to 100 mL of Overnight 
Express Instant TB media (Novagen) with ampicillin and grown at 37°C with shaking.  After 3 
hours, cultures were grown at 16°C for 24 hours with shaking. 
Cells were harvested by centrifugation at 5000 x g for 10 minutes at 4°C.  Each 100 mL pellet was 
resuspended in 8 mL of lysis buffer (50 mM sodium phosphate, pH 8.0, 0.3 M NaCl, 2.5 mM 
imidazole, 1x CelLytic B (Sigma-Aldrich), 5 mM β-mercaptoethanol (βME), 0.2 mg/mL lysozyme 
(Sigma-Aldrich), and 1 U Benzonase endonuclease (Merck)).  The lysate was centrifuged at 19000 
x g for 45 at 4°C and the supernatant collected. 
His-Select spin columns (Sigma-Aldrich) were equilibrated with 600 µL of equilibrium buffer (50 
mM sodium phosphate, pH 8.0, 0.3 M NaCl, 2.5 mM imidazole, and 5 mM βME).  The crude 
supernatant was applied to the columns and the columns were washed with 1200 µL of wash buffer 
(50 mM sodium phosphate, pH 8.0, 0.3 M sodium chloride, 5 mM imidazole, and 5 mM βME).  
The purified protein was eluted by the addition of 300 µL of elution buffer (50 mM sodium 
phosphate, pH 8.0, 0.3 M sodium chloride, 250 mM imidazole and 5 mM βME). 
Eluted protein was buffer exchanged into storage buffer (50 mM HEPES, pH 7.0, 10% glycerol, 
100 mM NaCl, 1 mM EDTA, and 5 mM DTT) with 0.5 mL 50K Amicon Ultra centrifugal filters 
(Millipore). 
 
Protein concentration determination 
Protein concentrations were determined by UV absorbance denaturation in 8 M guanidinium 
hydrochloride for 5 minutes at a dilution of 10x to 100x.  The extinction coefficient for each protein 
at 280 nm was calculated based on the number of tryptophans and tyrosines in the protein using 
ExPASy’s ProtParam tool. 
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Native PAGE to monitor conformation 
Native gel electrophoresis experiments were performed similar to those previously used to monitor 
the conformational state of TG2 [29, 36, 95].  5 µM TG2 was incubated for one hour at room 
temperature in preincubation buffer (75 mM imidazole, 0.5 mM EDTA, 5 mM DTT, pH 7.2) in 
each of four separate conditions: (1) no effectors, (2) 500 µM GTP and 1 mM MgCl2, (3) 5 mM 
CaCl2, and (4) 25 µM peptide inhibitor (Figure 2-2) and 5 mM CaCl2.  The peptide inhibitor was a 
gift from the Child Health and Development Institute.  After the incubation, the samples were 
diluted 2-fold with 2x sample buffer (0.125 M Tris, pH6.8, 20% glycerol, 0.005% (w/v) 
bromophenol blue, and 20 mM DTT).  Diluted samples were then added to Bio-Rad, 4-20% Mini-
PROTEAN® TGXTM precast gels and run at 4°C for 150 minutes at 125 V in Tris-glycine native 
running buffer.  Gels were stained with Coomassie blue and destained with destain solution (20% 
methanol, 10% acetic acid). 
 
Transglutaminase activity assay of TG2 catalyzed incorporation of dansylcadaverine into N,N-
dimethylated casein 
The TG2 catalyzed iospeptide bond formed between dansylcadaverine (DSC), (Sigma 30432), and 
one of the Gln residues of N,N-dimethylated casein (NMC), (Sigma C9801), was assayed by 
measuring the increase in dansyl fluorescence at 535 nm with an excitation wavelength of 350 nm 
at room temperature on a Safire2 microplate reader (Tecan) based on previous methods [96, 97].  
Reactions contained 20 nM TG2, 25 mM HEPES, pH 7.4,250 mM NaCl, 2 mM MgCl2, 0.5 mM 
CaCl2, 1 mM DTT, 0.05% Pluronic F-127, and 20 µM NMC.  Each of the 4 casein proteins that 
make up NMC has a minimum of 14 Gln residues.  The DSC concentrations ranged from 0 and 
1.5625 to 100 µM.  Reactions were initiated upon the addition of enzyme.  The rate of reaction 
versus the corresponding substrate concentration was fit to the Michaelis-Menten equation 
(equation 3), 
                                        v = Vmax[S]/Km + [S] (3) 
where v is the initial reaction rate, Vmax is the maximal rate of reaction, Km is the Michaelis constant, 
and [S] is the substrate concentration.   The experiment to test if an open-locked design (Y315E) of 
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TG2 could be active without Ca2+ was conducted exactly as above, but without the addition of 
CaCl2. 
 
Inhibition of transglutaminase activity by GTP 
The inhibition of TG2’s transglutaminase activity was conducted based on previous published 
protocols [97, 98].  Reactions contained 20 nM TG2, 25 mM HEPES, pH 7.4, 250 mM NaCl, 2 mM 
MgCl2, 0.5 mM CaCl2, 1 mM DTT, 0.05% Pluronic F-127, 80 µM N,N-dimethylated casein 
(NMC), (Sigma C9801), and 100 µM dansylcadaverine (DSC), (Sigma 30432). GTP was added to 
the reaction mixture at concentrations ranging from 0 to 500 µM.  Reactions were initiated upon the 
addition of enzyme.  Reaction progress was monitored at room temperature by measuring the 
increase in fluorescence intensity using an excitation wavelength of 350 nm and an emission 
wavelength of 535 nm on a Safire2 microplate reader (Tecan). 
 
Single turnover kinetic analysis for the GTPase reaction 
The GTPase reactions were performed at room temperature with γ-32P-GTP (GTP*) in 50 mM Tris-
HCl, pH 7.5, 4 mM MgCl2, 4 mM EDTA, 10% (v/v) glycerol, and 1 mM DTT as in [68].  Single 
turnover kinetics studies were performed as in [99].  Briefly, reactions were initiated upon the 
addition of GTP* to a final concentration of 1.68 nM and excess protein ( ≥ 10 µM).  At various 
time points, aliquots were removed from the reaction and quenched in 0.75 M potassium phosphate, 
pH 3.3.  The extent of the reaction was analyzed by thin-layer chromatography (PEI cellulose F) 
using 1 M formic acid and 0.5 M lithium chloride as the running buffer.  The ratios of product to 
substrate were then quantified with a phosphorimager (Storm 840; GE Healthcare). 
The reaction time courses were fit to equation 4, in which Frac(S) is the fraction of substrate GTP* 
remaining at each time point, a is the end point fraction of substrate, b is the initial fraction of 
substrate, and kobsd is the observed rate constant of the reaction [99]. 
                             Frac(S) = a + (b - a) exp(-kobsdt) (4) 
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The reaction time courses were fit to equation 2 assuming an endpoint (a) of 0.001.  The kobsd for 
each reaction was then plotted against the given enzyme concentration and fit to the Michaelis-
Menten-like equation 5 to plot kobsd, versus the concentration of TG2 to determine both kmax, the 
maximal rate constant with saturating protein, and K1/2, the protein concentration that provides half 
the maximal rate. 
                         kobsd = kmax x  [TG2]/(K1/2 + [TG2]) (5) 
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Results and Discussion 
Design of open-locked TG2 
After several rounds of hinge-focused design, Y315 was selected as the primary design residue for 
engineering open-locked TG2.  This residue is located in the hinge, which forms an α-helix in the 
open conformation and a β-strand in the closed (Figure 2-3).  In addition to being part of the hinge, 
Y315 was targeted for design because tyrosine strongly favors β-secondary structure over α, and 
because Y315 forms a hydrogen bond with the backbone of E329 in the closed structure (Figure 2-
3, B).  Therefore, we chose to force Y315 to an alanine or glutamate residue, both of which strongly 
favor α over β and would disrupt the hydrogen bond interaction in the closed conformation (Figures 
2-4 and 2-5).  However, the Y315E mutation was predicted to be forced into a hydrophobic pocket 
in the open conformation.  Therefore, subsequent rounds of design were conducted to accommodate 
the Y315E mutation in this hydrophobic pocket that surrounds Y315 in the native open 
conformation, which resulted in the Y315E_L508W and Y315E_L508T designs.  The threonine 
mutation in Y315E_L508T was predicted to make a favorable interaction with the sidechain of 
Y315E, while L508T’s CH3 group mimicked the native leucine’s sidechain facing into the structure 
(Figure 2-6).  The L508W in Y315E_L508W was predicted to accommodate the Y315E mutation 
by forcing the sidechain of Y315E to hydrogen bond with a native arginine residue (Figure 2-7). 
The β2-core interface design resulted in a 9-fold mutant (I178H, N181H, S253K, I255H, G256R, 
E557T, V665R, N667T, and K677T).  The WT residues are solvent-exposed in the open 
conformation and buried in the closed (Figure 2-8).  The polar mutations were predicted to 
destabilize the closed conformation and favor the open.  The initial two (Figure 2-9) and four 
(Figure 2-10) mutations were made (I178H_N181H and I178H_N181H_S253K_I255H, and 
respectively) along with the hinge designs were monitored for their conformation using native gel 
electrophoresis. 
WT TG2, when run on a native gel, adopted both the closed (high mobility) and open (low 
mobility) conformations.  Upon the addition of GTP, WT TG2 adopted the closed conformation and 
the open conformation was not observed.  When WT TG2 is run in the presence of calcium, the 
open conformation is observed, but usually a loss of protein occurs due to self-crosslinking and 
resulting precipitation.  The presence of an irreversible inhibitor in addition to calcium, however, 
inactivates the enzyme and forces it into the open conformation, resulting in a strong band of the 
open conformation (Figure 2-11).  These results agreed with previous findings [29]. 
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According to our native gels, all six open-locked designs were successful and adopted only the open 
conformation for all four conditions tested (Figure 2-11).  No high-mobility band was observed in 
any condition for any design.  Some designs showed a reduction in the amount of protein visible 
under the third condition (+ Ca2+), as with WT, indicating the enzyme was still active and was also 
self-crosslinking.  Indeed, upon the addition of calcium ions to some samples, precipitation was 
observed (data not shown).  Open-locked, active site knock out C277A_Y315E was also shown to 
adopt only the open conformation under all conditions (Figure 2-12). 
 
Design of closed-biased TG2 
The design residues selected for engineering a closed-stabilized TG2 (L312, E314, and F316) were 
all located on the hinge (Figures 2-13 and 2-14) and were distal from the tranglutaminasae active 
site residues in both conformations (Figures 2-15 and 2-16).  The closed stabilized calculations 
resulted in 23 suggestions that were made and run on native gels (Figure 2-17).  Most showed an 
increase in preference for the closed state in the first condition, where the enzyme is run on the 
native gel without any additives (see E314T and L312I_E314T, for example).  Some showed no 
large change from WT behavior for all for conditions (L312V_F316V).  Others (such as L312Y and 
F316T) had bands for both the open and closed conformations in the third condition (+ Ca2+, which 
drives WT to adopt the open conformation).  Some designs exhibited an intermediate band (see 
L312Y condition 3). 
The most dramatic changes in conformational preferences were found in designs E314T_F316T, 
L312V_F316T, and especially L312Y_F316T.  L312Y_F316T appears to prefer the closed 
conformation in conditions one through three, unlike WT.  All designs still adopted the open 
conformation upon inhibition by the covalent inhibitor, however, implying that the binding of the 
inhibitor forces the adoption of the open conformation.  These results led us to conclude that while 
several of our designs showed a marked preference over WT for the closed conformation, yet were 
still able to adopt the open conformation when bound to inhibitor, we had designed  “closed-biased” 
variants of TG2 rather than closed-locked. 
 
Transglutaminase activity of the open-locked designs of TG2 
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All open-locked design showed significantly less activity than WT TG2 (see Figures 2-20, 2-22 and 
Table 2-1).  The most active open-locked design suffered a 70% loss in activity relative to WT 
TG2.  This result was unexpected, given that the open form of the enzyme is the one adopted by the 
WT enzyme in the presence of calcium ions and was believed to be the transglutaminase active 
conformation.  The expected outcome was that these open-locked designs would be more active 
than WT TG2 because the initial opening of the enzyme was accomplished and maintained.  WT 
TG2 was determined to have a Vmax of 1.6 ± 2.5% FI/s.  Y315E was the most active open-locked 
design with a Vmax of 0.49 ± 8.6% FI/s, and the least active open-locked design had a Vmax of 0.10 ± 
23% FI/s. 
 
Role of calcium ions in transglutaminase activity 
The role of calcium in transglutaminase activity is not fully understood.  As discussed in the 
introduction, calcium is necessary for transglutaminase activity and causes the enzyme to adopt the 
open conformation.  But what effect of Ca2+ binding is making it necessary for transglutaminase 
activity?  Is driving the adoption of the open conformation calcium’s only role in achieving 
transglutaminase activity?  And, therefore, would an open-locked version of TG2 still need calcium 
in order to be active?  Or, is calcium not only involved in large-scale conformational regulation, but 
also plays some unknown role in catalysis?  In order to investigate these questions, we tested the 
transglutaminase activity of the most active open-locked design, Y315E, in the absence of calcium 
ions.  If calcium’s only role in transglutaminase activity is to force the adoption of the open 
conformation, and this conformation is active in and of itself, Y315E should have been active 
despite the absence of calcium ions.  However, under these conditions, Y315E without calcium had 
no observable transglutaminase activity (Figure 2-21).  Therefore, the Ca2+ dependence of TG2’s 
transglutaminase activity arises from more than the calcium-induced large-scale conformational 
opening of TG2. 
What Ca2+ is doing to promote activity besides causing the enzyme to adopt the open form is 
unclear.  Perhaps smaller conformational changes induced by the binding of these ions, as seen in 
TG3, where loops surrounding bound Ca2+ exhibit small conformational movements, also occur in 
TG2, and these small changes induce activity.  The oxidation of TG2, which is inactivating, also 
causes the adoption of the open conformation, and the mechanism of this inactivation is not fully 
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understood.  It is clear, however, that merely being “open” is not sufficient for TG2 to exhibit 
transglutaminse activity. 
 
Transglutaminase activity of the closed-biased designs of TG2 
Because the adoption of the closed conformation was believed to be the mechanism by which GTP 
inhibits TG2’s transglutaminase activity, we expected that the closed-biased designs would be 
significantly less active than WT and open-locked TG2.  However, all of the closed-biased designs 
assayed for transglutaminase activity were more active than any of the open-locked designs, except 
closed-biased E314T, which was less active than 4 open-locked designs (see Figure 2-22 and Table 
2-1).  In addition, four of the closed-biased designs were more active than WT TG2: L312Y, 
L312V, L312Y_F316T (the “most closed”), and F316T.  Of all of the designs, open and closed, 
only L312I_E314T had a significant change in apparent Km, although the error in this value was 
large. 
The increase in TG2 activity of some closed-biased designs was a surprising result, and came on the 
heels of the discovery that the open-locked TG2s exhibited decreased transglutaminase activity.  
Taken together, these results were the opposite of what was expected, causing us to look back at 
other confusing results in regards to TG2 transglutaminase activity. 
As mentioned in Chapter 1 and this chapter’s introduction, several studies have cast doubt on the 
current model of transglutaminase activity.  Two truncation studies showed that deletion of the C-
terminal β-barrels resulted in a loss in transglutaminase activity despite these domains being very 
distal from the transglutaminase active site in the assumed active open conformation [68, 69].  Both 
factor XIII and TG3 are able to catalyze the transglutaminase reaction albeit more specifically than 
TG2, despite being shown to adopt the closed conformation in the presence of calcium [38, 57, 58] 
[55, 59].  The active site residues of TG2 adopt largely the same conformation in both the open sand 
closed conformations (see Figures 2-23 and 2-24), and TG2’s active site residues in the closed 
conformation also align well to the active site residues of TG3 in the active conformation bound to 
calcium (Figure 2-25) [29, 30, 53].  Additionally, celiac patients' autoantibodies against TG2 have 
been shown to increase transglutaminase activity of TG2 and bind a motif that is complete only in 
the closed conformation [81, 83, 87, 88].  These results led the authors to propose that TG2 might 
be more active as a transglutaminse in the closed conformation. 
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Our results support this hypothesis and help to clarify the previously mentioned observations of the 
apparent need for the β-barrel domains and those results that called into question the necessity of 
the open conformation for transglutaminase activity.  However, since all designs still adopted the 
open conformation upon inhibitor binding, it may be possible that this open conformation is 
necessary for activity in that it helps to accommodate substrates, and that this explains the relative 
promiscuity of TG2 for glutamine substrates compared to its less open relations TG3 and factor 
XIII.  Perhaps an equilibrium between the two structures exist during catalysis, and the enzyme 
cycles through the conformations during the various steps of the transglutaminase reaction.  It is 
also possible that a shift towards favoring the closed conformation helps the enzyme move through 
a rate-limiting step.  Single molecule experiments to monitor the motion of the enzyme during 
catalysis and a deamidase assay as in [87] would further our understanding of the role of each 
conformation in the mechanism of  the TG2-catalyzed transglutaminase reaction. 
 
Inhibition of transglutaminase activity by GTP 
No large differences in the inhibition of transglutaminase activity by GTP were observed between 
WT TG2 and closed-biased L312Y when analyzed by the percent of the variant’s own activity lost 
(Figure 2-26) or by the percent of WT activity lost (Figure 2-27).  However, open-locked 
Y315E_L508W lost less of a percent of its own activity, relative to WT (Figure 2-26) and was more 
active than WT at high GTP concentrations (Figure 2-28), implying that it was less susceptible to 
inhibition by GTP. 
These results were expected, in the sense that closed-biased L312Y and WT TG2 were not expected 
to behave too differently given they adopt the same conformation in the presence of GTP.  Also, 
open-locked Y315E_L508W was expected to be less susceptible to GTP inhibition given its active 
site is disrupted upon the adoption of the open conformation.  However, Y315E_L508W was still 
susceptible to inhibition by GTP to the point of retaining only approximately 20% of its uninhibited 
activity at 500 µM GTP; the same concentration of GTP used in the native gels in condition two 
where Y315E_L508W still adopted the open conformation (see Figure 2-11).   
The mechanism by which GTP was thought to inhibit transglutaminase activity was by forcing the 
adoption of the closed conformation, thereby obscuring access to the transglutaminase active site.  
The susceptibility of open-locked TG2 to inhibition by GTP despite it being shown that the enzyme 
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remains open at high GTP concentrations and the fact that closed-biased designs showed at times 
increased transglutaminase activity relative to WT call this theory into question, and suggest that 
some alternative mechanism of inhibtion may be at work.  One study suggested that a set of 
conserved tryptophan residues in the core of the protein were important in GTP inhibition of 
transglutaminase activity, and may be involved in “allosteric relay machinery” that propagates 
inhibitory effects from GTP binding to the transglutaminase active site [100].  Repeating the study 
detailed in the above paper with open-locked TG2 to investigate if these tryptophan residues would 
still be involved in GTP inhibition of transglutaminase activity would be enlightening. 
 
Single turnover kinetic analysis of the GTPase of WT, open-locked, and closed-biased TG2 
Single turnover kinetics, where enzyme is saturating, were used to analyze the GTPase activity of 
WT TG2 and our designs because it enabled us to avoid complications arising from rate limiting 
product dissociation.  Due to time constraints, the determination of conditions for the WT assay and 
an initial assay of WT plus open-locked Y315E_L508W, closed-biased and most active L312Y, and 
most closed closed-biased, and more active than WT protein L312Y_F316T were the only 
experiments accomplished.  Therefore, this assay needs to be further optimized and repeated.   
However, initial results were dramatic and unexpected (Figure 2-29 and Table 2-2).  GTPase 
activity increased with increasing preference for the open conformation, with open-locked 
Y315E_L508W being the most active GTPase and most closed closed-biased L312Y_F316T being 
the least active.  As detailed in Chapter 1, the binding of GTP induces the adoption of the closed 
conformation, and the residues which make up the GTPase active site in the crystal structure of 
closed TG2 involve residues in the core and β-barrel 1 domain, which are torn appart in the open 
structure.  Therefore, we expected that the closed-biased TG2s would be more active as a GTPase 
than WT, and that the open-locked TG2 would be the least active.  These results indicate the exact 
opposite. 
This result corroborates the results of the two truncation studies mentioned in the introduction, 
where the core of the protein minus the β-barrel domains was found to be more active as a GTPase 
than full length protein [68, 69].  These results suggest that the closed form of TG2 may do more to 
regulate GTPase activity than promote it, and call into question the current understanding of the 
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GTPase active site.  A crystal structure of open-locked TG2 bound to GDP would be useful in 
furthering our understanding of the mechanism of TG2 as a GTPase. 
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Conclusions 
In summary, we were successful in designing open-locked and closed-biased variants of TG2 using 
computational protein design.  These designs allowed us to characterize the activities of these 
conformations, and resulted in conclusions about the behavior of TG2 opposite to the current 
understanding, but which clarified and supported previous studies.  The existing model for TG2 
conformational behavior and catalytic activity was that the open form of TG2, adopted upon 
calcium binding, catalyzed only the transglutaminase reaction and the closed form, adopted upon 
the binding of GTP, catalyzed only the GTPase reaction.  Our designs allowed us to determine three 
previously unknown characteristics of TG2: (1) the open conformation of TG2 is insufficient for 
transglutaminase activity, and therefore that the Ca2+-dependence of this reaction is derived from 
more than driving conformational change, (2) the closed-biased designs of TG2 have higher 
transglutaminase activity than the open-locked designs, and in some cases, WT, and (3) not only 
can both conformations act as a GTPase, but the open-locked TG2 is significantly more active than 
the WT or closed-biased designs. 
These results have immense implications for the understanding of TG2’s behavior in biology and 
the targeting of this enzyme for disease therapy.  These results also explain previously confusing 
truncation studies, help explain the various substrate specificities among the transglutaminase 
family, and lend credence to the idea that celiac anti-TG2 antibodies could be increasing 
transglutaminase activity by stabilizing the closed conformation, and therefore this conformation 
should be used as a model for designing small molecule transglutaminse inhibitors for drug 
development. 
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Figure 2-1.  Design regions of TG2.  The domains of TG2 are illustrated in cartoon form for the 
open and closed conformations (right and left respectively).  The two regions to be targeted as 
design regions are (A) the β2-core interface, and (B) the hinge. 
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Figure 2-2.  Irreversible transglutaminase inhibitor of TG2 provided by the CHDI. 
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Figure 2-3.  Open-locked design hinge residue Tyr315 for in the WT crystal structures.  (A) Y315 
in the open form of TG2 is nestled in a pocket on the β1-barrel [29].  (B) In closed TG2, Y315 
forms a hydrogen bond with the backbone of E329 [30]. 
 
 
Figure 2-4.  TRIAD predicted structure for open-locked design Y315A.  (A) In the open structure, 
the alanine mutation does not fill the pocket normally occupied by the Y315 sidechain.  (B) In the 
closed structure, alanine is unable to form the hydrogen bond and leaves a whole in the closed form 
of the enzyme. 
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Figure 2-5.  TRIAD predicted structure for open-locked design Y315E.  (A) In the open structure, 
the glutamine residue is forced into the hydrophobic pocket.  (B) In the closed structure, the 
sidechain of Y315E makes an unfavorable interaction with the backbone of E329. 
 
 
Figure 2-6.  TRIAD predicted structure for open-locked design Y315E_L508T.  (A) In the open 
form, the L508T mutation is predicted to make a favorable interaction with the Y315E sidechain to 
help accommodate it in the pocket.  The CH3 group of L508T mimics the WT L508 sidechain.  A 
WT R506 residue is also predicted to flip inwards toward Y315E.  (B) In the closed structure, the 
sidechain of Y315E makes an unfavorable interaction with the backbone of E329. 
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Figure 2-7.  TRIAD predicted structure for open-locked design Y315E_L508W.  (A) In the open 
form, L508W is predicted to force the sidechain of Y315E to interact with R506.  (B) In the closed 
structure, the sidechain of Y315E makes an unfavorable interaction with the backbone of E329 . 
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Figure 2-8.  Open-locked WT design residues for the β2-core interface in the WT structure.  (A) In 
the open conformation, the design residues are solvent exposed on both the core of the protein and 
on β barrel 2 [29].  (B) In the closed conformation, these residues are buried [30]. 
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Figure 2-9.  TRIAD prediction of open-locked core design residues I178H and N181H for the β2-
core interface in the open conformation (A) and the closed conformation (B). 
 
 
Figure 2-10.  TRIAD prediction of open-locked core design residues I178H, N181H, S253K, and 
I255H for the β2-core interface in the open conformation (A) and the closed conformation (B). 
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Figure 2-11.  Native gels of open-locked designs showing that all designs adopt the open 
conformation under all conditions.  Set of four conditions on the left of each gel are for the WT 
protein, and the right side shows the results for the indicated design.  The conditions are as follows: 
(1) purified WT TG2 or design only, (2) protein with 500 µM GTP and 1 mM MGCl2, (3) protein 
with 5 mM CaCl2, and (4) protein with 5 mM CaCl2 and 25 µM irreversible peptide inhibitor. 
 
Figure 2-12.  Native gel of WT and open-locked and active site knock-out C277A_Y315E.  The 
conditions are as follows: (1) purified WT TG2 or design only, (2) protein with 500 µM GTP and 1 
mM MGCl2, (3) protein with 5 mM CaCl2, and (4) protein with 5 mM CaCl2 and 25 µM irreversible 
peptide inhibitor. 
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Figure 2-13.  Closed-locked WT design residues in the closed form of TG2: L312, E314, and F316 
[30]. 
 
Figure 2-14.  Closed-locked WT design residues in the open form of TG2 [29]. 
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Figure 2-15.  Closed-locked WT design residues in the closed conformation of TG2 are located 
distally from the transglutaminase active site [30]. 
 
 
Figure 2-16.  Closed-locked WT design residues in the open conformation of TG2 are located on 
the hinge just below the end of the inhibitor on the opposite side of the hinge [29]. 
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Figure 2-17.  Native gels of closed-biased designs.  Conditions 1 through 4 are the same for each 
indicated TG2 variant.  The conditions are as follows: (1) purified WT TG2 or design only, (2) 
protein with 500 µM GTP and 1 mM MGCl2, (3) protein with 5 mM CaCl2, and (4) protein with 5 
mM CaCl2 and 25 µM irreversible peptide inhibitor. 
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Figure 2-18.  TRIAD prediction of closed-biased hinge design residue L312Y in orange in the open 
conformation (A) and the closed conformation (B). 
 
Figure 2-19.  TRIAD prediction of closed-biased hinge design residues L312Y_F316T in orange in 
the open conformation (A) and the closed conformation (B). 
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Figure 2-20.  Transglutaminase activity assay of TG2 catalyzed incorporation of dansylcadaverine 
into N,N-dimethylated casein for WT and open-locked designs.  WT protein had much greater 
activity than any of the open-locked designs. 
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Figure 2-21.  Transglutaminase activity assay of TG2 catalyzed incorporation of dansylcadaverine 
into N,N-dimethylated casein for WT and open-locked design Y315E with and without calcium.  
The adoption of the open conformation alone is not sufficient for transglutaminase activity. 
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Figure 2-22.  Kinetic data for the transglutaminase activity assay of TG2 catalyzed incorporation of 
dansylcadaverine into N,N-dimethylated casein for WT and all designs.  Open-locked residues are 
in red, closed-biased in black, and WT in blue. 
  
  
69 
Table 2-1.  Kinetic data for the transglutaminase activity assay of TG2 catalyzed incorporation of 
dansylcadaverine into N,N-dimethylated casein for WT and all designs, in the order of decreasing 
activity. 
TG2 Variant Vmax (FI/s)  Apparent Km (µM) 
L312Y 2.0 ± 0.98% 3.8 ± 4.2% 
L312V 1.8 ± 3.0% 3.1 ± 14% 
L312Y F316T 1.8 ± 1.5% 1.9 ± 7.9% 
F316Y 1.7 ± 5.6% 3.8 ± 24% 
WT 1.6 ± 2.5% 3.1 ± 11% 
F316T 1.4 ± 2.5% 2.9 ± 12% 
L312I E314T 1.3 ± 19% 18 ± 54% 
F316V 1.3 ± 1.9% 1.3 ± 12% 
E314T F316V 1.0 ± 4.2% 2.2 ± 21% 
L312I E314T F316V 0.93 ± 4.7% 2.4 ± 23% 
L312I F316V 0.93 ± 1.6% 2.8 ± 7.6% 
L312V F316T 0.92 ± 4.1% 1.6 ± 23% 
L312V E314T F316V 0.53 ± 6.0% 4.7 ± 24% 
Y315E 0.49 ± 8.6% 3.9 ± 37% 
Y315E L508W 0.47 ± 3.5% 3.1 ± 16% 
I178H N181H 0.44 ± 5.9% 5.3 ± 23% 
Y315E L508T 0.33 ± 2.0% 5.0 ± 7.6% 
E314T 0.32 ± 4.8% 2.7 ± 23% 
I178H N181H S253K I255H 0.11 ± 7.8% 0.43 ± 91% 
Y315A 0.10 ± 23% 0.28 ± 340% 
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Figure 2-23.  The active site residues of the transglutaminase site of TG2 assume similar 
conformations in both the open and closed forms of the enzyme [29, 30]. 
 
Figure 2-24.  The catalytic triad overlays well in both the open and closed conformations.  The open 
conformation is shown in pink with its catalytic triad in red.  The closed conformation is shown in 
gray and its catalytic triad is shown in black [29, 30]. 
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Figure 2-25.  Overlay of the transglutaminase active sites of the closed form of TG2 (pink protein, 
red active site residues) and the closed, active, and calcium-bound form of TG3 (purple protein, 
magenta active site residues) [30, 53]. 
  
72 
 
Figure 2-26.  Inhibition of transglutaminase activity by GTP for WT, open-locked Y315E_L508W, 
and closed-biased L312Y as shown as percent of each variants own uninhibited activity. 
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Figure 2-27.  Inhibition of transglutaminase activity by GTP for WT and closed-biased L312Y as 
shown as percent of WT’s uninhibited activity. 
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Figure 2-28.  Inhibition of transglutaminase activity by GTP for WT and open-locked 
Y315E_L508W as shown as percent of WT’s uninhibited activity. 
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Figure 2-29.  Single turnover kinetic analysis for the GTPase reaction for WT TG2, open-locked 
Y315E_L508W, closed-biased and most transglutaminase active L312Y, and most closed-biased 
L312Y_F316T.  These concentration dependencies are fit to equation 5 to determine kmax, the 
maximal rate constant with saturating protein, and K1/2, the protein concentration that provides half 
the maximal rate. 
Table 2-2.  Summary of rate and equilibrium constants for the single turnover GTPase reaction of 
TG2 variants. 
TG2 Variant kmax (min-1) K1/2 (µM) 
WT 0.014 ± 0.014 460 ± 550 
Y315E L508W 0.01 ± 0.0020 3.4 ± 4.9 
L312Y 0.0058 ± 0.0076 370 ± 720 
L312Y F316T 0.0013 ± 0.00034 68 ± 51 
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C h a p t e r  3  
THE ADDITION OF TG2 DESIGNS WITH DISTINCT CONFORMATIONS AND ACTIVITIES 
ELICIT DIFFERENTIAL EXPRESSION OF CELIAC-RELATED GENES IN CELL CULTURE 
Abstract 
Celiac disease is an autoimmune condition affecting the small intestine in response to the ingestion 
of gluten in affected individuals.  The primary autoantigen in celiac disease is type II 
transglutaminase (TG2), and these anti-TG2 antibodies themselves have been shown to induce anti-
angiogenic and other pathogenic effects in endothelial models similar to those seen in celiac 
patients, including the up-regulation of genes like E-selectin.  In celiac disease, TG2’s 
transglutaminase activity contributes to pathogenesis by catalyzing the deamidation of gluten, 
which facilitates the binding cascade that leads to the autoimmune response.  Recently, celiac 
autoantibodies have been shown to increase the transglutaminase activity of TG2 and bind a motif 
on the enzyme that is fully assembled only in the closed conformation, suggesting that the 
stabilization of the closed conformation may be leading to this increase in activity.  Indeed, the 
results of Chapter 2 support this hypothesis.  The goal of this chapter was to test if the increase in E-
selectin expression and the other anti-angiogenic effects induced by celiac anti-TG2 antibodies are 
derived from their increasing of transglutaminase activity.  In order to accomplish this, we utilized 
the design variants detailed in Chapter 2 to investigate if conformationally distinct forms of TG2 
with differing levels of transglutaminase activity could elicit differing effects in cell culture, and to 
further investigate the hypothesis that the stabilization of the closed conformation and the resulting 
increase in transglutmainase activity of TG2 led to pathogenic effects observed in CD.  Using 
qPCR, we found that the addition of TG2 variants, including a transglutaminase knockout, to 
HUVEC culture did increase the activation of NF-κB (which is activated in celiac disease) and 
increased E-selectin expression.  The increases in E-selectin among closed-biased and WT TG2 did 
increase with increasing transglutaminase activity, but open-locked knocked-down and knocked-out 
versions of TG2 also increased NF-κB activiation and E-selectin expression, making it impossible 
to conclude from this initial study if increased transglutaminase activity alone is responsible for 
these aberrations.  Further studies investigating possible transglutaminase activity independent 
mechanisms of pathway activation are therefore indicated.  
  
84 
Introduction 
The transglutaminase activity of TG2 plays a critical role in celiac disease 
Celiac disease (CD) is an intestinal autoimmune condition triggered in genetically predisposed 
individuals by the ingestion of gluten. [1, 2].   In CD, TG2 deamidates gluten peptides in the small 
intestine, increasing their binding affinity for mutant major histocompatibility complex (MHC) 
class II molecules, which elicits the autoimmune response [3-8].  The primary autoantigen in celiac 
disease is also TG2 [3], and a primary hallmark of CD is the secretion of anti-TG2 antibodies into 
the small intestinal mucosa where they bind extracellular TG2 on fibroblasts surrounding mucosal 
blood vessels [9-13]. 
 
CD anti-TG2 antibodies affect angiogenesis 
Chapter 1 details the ability of CD anti-TG2 autoantibodies to cause pathogenic symptoms in 
endothelial models [14-22].  One such effect is the ability of CD antibodies to enhance lymphocyte 
binding to the endothelium and their transendothelial migration, which is complemented by a more 
than 2-fold up-regulation in expression of E-selectin, a lymphocyte adhesion molecule [17].  This 
up-regulation in E-selectin [17] was determined by adding celiac antibodies at a concentration of 1 
µg/mL to human umbilical vein endothelial cells (HUVECs) for 24 hours, and then analyzing them 
for E-selectin protein expression by flow cytometry and immunofluorescent staining.  These effects 
are relevant and suggestive because increased levels of adhesion molecules crucial to the 
inflammatory response and lymphocyte migration, such as E-selectin, are also observed in untreated 
celiac disease [23-25].  
Many other studies have investigated celiac total IgA and purified celiac anti-TG2 autoantibodies’ 
ability to inhibit angiogenesis and increase vascular permeability [17-22].  One study [20] used 
microarray technology to analyze the expression of a set of angiogenesis and endothelial cell 
biology genes in HUVECs after a 24 hour treatment with either total IgA from celiac or control 
patients, or monoclonal control or anti-TG2 celiac miniantibodies, also at a concentration of 1 
µg/mL. Compared to control, total IgA up-regulated the expression of four genes, and down-
regulated the expression of six.  Of these ten genes, three were selected for RT-PCR analysis and 
confirmed for differential expression: integrin beta 1 (ITGB1) decreased by a factor of 0.73; 
fibronectin 1 (FN1) increased by a factor of 1.2; and ras homolog gene family member B (RHOB) 
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increased by a factor of 1.26.  RHOB was found to be similarly up-regulated in gene expression by 
monoclonal anti-TG CD antibodies, and RhoB protein expression was also increased by a factor of 
approximately 1.45 by both total IgA and monoclonal anti-TG2 CD antibodies. 
 
CD anti-TG2 antibodies increase TG2 transglutaminase activity 
CD anti-TG2 autoantibodies have been reported to increase the transglutaminase activity of TG2 
[17, 19, 26].  In the celiac patient, an increase in transglutaminase activity could potentially increase 
the enzyme’s ability to deamidate gluten, creating a positive feedback loop where the disorder 
reinforces itself by increasing TG2’s ability to create more binding partners for the mutant MHC 
class II molecules [19].   
Because the celiac antibodies were found to be transglutaminase activating, it was believed that the 
antibodies might be stabilizing a more active form of TG2 [26].  Recently, the TG2 epitope 
recognized by these celiac autoantibodies was identified to be a conformationally dependent one 
comprising residues from three different domains: the N-terminus, the core, and β-barrel 2 [27].  
Because of their differing locations, the residues are only spatially close to each other when the 
enzyme adopts the closed conformation.  Therefore, if the antibodies are increasing the activity of 
TG2, they may be doing so by stabilizing the closed conformation of the enzyme, which was 
traditionally believed to be the transglutaminase inactive form.   
 
Nuclear factor-κB is activated in the intestinal mucosa in celiac disease 
Nuclear factor-κB (NF-κB) is a transcription factor that regulates immune and inflammatory 
responses [28, 29], and is activated in biopsy specimens of celiac patient small intestinal mucosa 
[30].  This activation is highest in untreated celiac patients, and decreases upon treatment, yet 
remains higher than control subjects [30]. 
Suggestively, TG2 expression and activity is closely connected with NF-κB activation.  Studies 
investigating chemoresistance of various cancers showed both tumor cells overexpressing TG2 and 
the activation of TG2 in such cells led to the activation of NF-κB [31].  In addition, both the 
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inhibition of transglutaminase activity and the knock-down of TG2 expression by RNAi inhibited 
NF-κB activation [31, 32].   
TG2 gene and protein expression is tightly correlated with NF-κB activity [32, 33].  In fact, TG2 
and NF-κB have been shown to exist in a self-reinforcing feedback loop, where TG2 activates NF-
κB, and in return NF-κB induces further TG2 expression [33-35].  On a related note, TNF-α, an 
inducer of NF-κB , has also been shown to up-regulate E-selectin [36, 37].   
The mechanism by which TG2 activates NF-κB is still not fully understood, but TG2 has been 
shown to activate NF-κB by inducing the depletion of inhibitory subunit α of NF-κB (IκBα or 
NFKB1A), and thereby preventing it from inhibiting NF-κB [38-40].  The proposed mechanism of 
this depletion of IκBα is the crosslinking of IκBα by TG2, resulting in its polymerization and 
inability to inhibit NF-κB [38].  This theory is contested, however, by a study showing that the 
overexpression of WT TG2 and the active site knockout TG2 mutant C277S were both able to 
activate NF-κB in mammary epithelial cells, although they also concluded that this activation was 
produced by the depletion of IκBα, and that IκBα associated in complexes with TG2-C277A [41]. 
 
TG2 stabilized in various conformations with varying levels of TGase activity are a new tool 
The above studies found that autoantibodies against TG2 isolated from celiac patients increase TG2 
transglutaminase activity and bind a motif that exists in the closed conformation, suggesting that the 
stabilization of this conformation leads to the increase in activity.  This hypothesis is supported by 
the findings detailed in Chapter 2 that the transglutaminase activities of the open-locked designs of 
TG2 are significantly decreased compared to WT and closed-biased TG2 designs.  If the increase in 
adhesion protein expression and the anti-angiogenic effects of adding anti-TG2 autoantibodies to 
the media of cultured HUVECs are mediated by the binding of these antibodies to extracellular 
TG2, and the resulting increase in activity, it is conceivable that the addition of TG2 to the media of 
HUVECs could induce a similar response.   
In fact, adding TG2 to the media of HUVECs has been shown to elicit anti-angiogenic effects: a 
previous study showed the addition of WT TG2 to HUVEC culture at 50 µg/mL resulted in the 
accumulation of extracellular matrix (ECM), leading to the anti-angiogenic characteristic of 
suppressed endothelial tubule formation [42] similar to that seen in investigations of CD 
autoantibodies’ anti-angiogenic effects [17-20, 22, 27].  
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The previous chapter describes the design of variants of TG2 preferring either the open or the 
closed conformation.  Having such designs available provided the unique opportunity to investigate 
if conformationally distinct forms of TG2 with differing levels of transglutaminase activity could 
elicit differing effects in cell culture, and to further investigate the hypothesis that the stabilization 
of the closed conformation and the resulting increase in transglutmainase activity of TG2 led to 
pathogenic effects observed in CD.  In this chapter, using qPCR, we probed both the activation of 
NF-κB and the expression-level response of genes shown to be affected by the addition of celiac 
anti-TG2 autoantibodies to the addition of various TG2 variants to HUVEC cell culture, similar to 
the methods used in the celiac autoantibody studies detailed above.  The variants used included the 
transglutaminase inactive and open-conformation-adopting C277A_Y315E, open-locked 
Y315E_L508W (Vmax 0.47 FI/s) with low transglutaminase activity, WT TG2 (Vmax 1.6 FI/s), and 
closed-biased L312Y (Vmax 2.0 FI/s) and L312Y_F316T (Vmax 1.8 FI/s) with higher than WT 
transglutaminase activity. 
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Methods 
Protein expression and purification 
LB/ampicillin starter cultures were inoculated from a glycerol stock of BL-21 (DE3) Gold E. coli 
containing the expression vector pET11a (Novagen) with the gene for the variant of interest and 
grown overnight at 37°C with shaking.  4 mL of starter culture were added to 100 mL of Overnight 
Express Instant TB media (Novagen) with ampicillin and grown at 37°C with shaking.  After 3 
hours, cultures were grown at 16°C for 24 hours with shaking. 
Cells were harvested by centrifugation at 5000 x g for 10 minutes at 4°C.  Each 100 mL pellet was 
resuspended in 8 mL of lysis buffer (50 mM sodium phosphate, pH 8.0, 0.3 M NaCl, 2.5 mM 
imidazole, 1x CelLytic B (Sigma-Aldrich), 5 mM β-mercaptoethanol (βME), 0.2 mg/mL lysozyme 
(Sigma-Aldrich), and 1 U Benzonase endonuclease (Merck)).  The lysate was centrifuged at 19000 
x g for 45 at 4°C and the supernatant collected. 
His-Select spin columns (Sigma-Aldrich) were equilibrated with 600 µL of equilibrium buffer (50 
mM sodium phosphate, pH 8.0, 0.3 M NaCl, 2.5 mM imidazole, and 5 mM βME).  The crude 
supernatant was applied to the columns and the columns were washed with 1200 µL of wash buffer 
(50 mM sodium phosphate, pH 8.0, 0.3 M sodium chloride, 5 mM imidazole, and 5 mM βME).  
The purified protein was eluted by the addition of 300 µL of elution buffer (50 mM sodium 
phosphate, pH 8.0, 0.3 M sodium chloride, 250 mM imidazole and 5 mM βME). 
Eluted protein was buffer exchanged into storage buffer (50 mM HEPES, pH 7.0, 10% glycerol, 
100 mM NaCl, 1 mM EDTA, and 5 mM DTT) with 0.5 mL 50K Amicon Ultra centrifugal filters 
(Millipore). 
 
Protein concentration determination 
Protein concentrations were determined by UV absorbance denaturation in 8 M guanidinium 
hydrochloride for 5 minutes at a dilution of 10x to 100x.  The extinction coefficient for each protein 
at 280 nm was calculated based on the number of tryptophans and tyrosines in the protein using 
ExPASy’s ProtParam tool. 
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Cell culture 
Human umbilical vein endothelial cells (HUVECs) (Invitrogen and Lonza) were cultured in 
Endothelial Growth Media-2 (EGM-2 Medium; Lonza).  EGM-2 consists of Endothelial Cell Basal 
Medium-2 (EBM-2; Lonza) and the endothelial cell growth factors in the EGM-2 Bulletkit (Lonza).  
Cells were cultured on type I collagen-coated plates at 37°C in a 5% CO2 incubator. 
 
Gene expression assay of treated cell cultures 
HUVECs were plated at 10,000 cells/cm2.  After 20 hours, new media was added to the culture 
wells.  The enzymes under investigation were WT, transglutaminase active site knockout 
C227A_Y315E, closed biased L312Y or L312Y_F316T, or open-locked Y315E_L508W.  All 
enzymes were added to the media at a final concentration 5 µg/mL.  Tumor necrosis factor α (TNF-
α) (Sigma-Aldrich) was used as a positive control for NF-κB activation and therefore NFKB1A 
expression [43] and was added at a final concentration of 10 ng/mL.  Three negative controls 
consisted of either the addition of storage buffer without enzyme, the active site knockout 
C227A_Y315E, or untreated cells.  Time points were investigated by adding the enzyme or control 
effectors either when the new media was added, 12 hours after, or 21 hours after, resulting in 
samples that were treated for 24, 12, or 3 hours, respectively.  Total RNA was extracted using the 
RNAeasy Kit (Qiagen) according to the manufacturer’s protocol.  Experiments were done with a 
biological replicate. The experiment was performed twice, the first time with cells from Invitrogen, 
the second time with cells from Lonza.  All experiments were performed on passages 2 through 5. 
 
qPCR 
The comlementary DNA (cDNA) was synthesized using the iScript cDNA Synthesis Kit (BioRad) 
using 0.5 µg of RNA.  Quantitative PCR was performed on a BioRad CFX96 Real Time System 
with 1/50th of the cDNA reaction, single gene PrimeTime qPCR 0.5 µM/0.25 µM final primer/probe 
mixtures from IDT (see Table 3-1), and SsoFast Probes Supermix (BioRad) in a total volume of 10 
µL.  All probes used the fluorophore FAM.  The cycling conditions consisted of an initial 
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denaturation for 30 s at 95°C, followed by 39 cycles of 5 s at 95°C and 10 s at 60°C.  Each 
biological replicate was performed with a technical replicate.  NF-κB activation was monitored by 
measuring the changes in expression of NFKB1A as described previously [43].  The expression 
level of genes was determined by the relative quantity method with the control expression level 
being that found in untreated cells, and normalized using the geometric mean of the housekeeping 
genes GAPDH, SDHA, and TBP.   
 
Statistical analysis 
Data are presented as mean ± standard error of mean (SEM).  Statistical analysis was performed 
using the Student’s t test with the Bonferroni correction, where the p<0.05 was considered 
significant.  The Bonferroni correction for these data sets resulted in a modified p value 0.002 for a 
two-tailed test.     
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Results  
When the Bonferroni correction was used to analyze the data with 21 pairwise comparisons, both 
NFKB1A and SELE were affected relative to buffer by various proteins in observations deemed 
statistically significant (p<0.05).  However, no statistically significant changes in FN1, ITGB1, or 
RHOB relative expression were observed in this study (see Tables 3-14 through 16 and Figures 3-5 
through 3-10).  Results were qualitatively reproducible between experiments using different 
HUVEC sources (Figures 3-1 through 3-10).   
Closed-biased L312Y_F316T and L312Y, as well as TNF-α were the only proteins whose effects 
on NFKB1A were determined to be statistically significant.  After the 3-hour treatment, 
L312Y_F316T and L312Y showed increases in NFKB1A expression relative to buffer ranging 
from 4-fold to almost 6-fold (Table 3-2 and Figures 3-1, 3-2).   In experiment 2, an increase in 
NFKB1A expression relative to buffer was seen for L312Y after 12 hours, and for L312Y_F316T 
after 24 hours (Table 3-2 and Figure 3-2).  
TNF-α, C277A_Y315E, and Y315E_L508W all caused an increase in the mean relative expression 
level of NFKB1A, but due to larger errors, were deemed statistically insignificant, although the 
response to TNF-α after 12 hours in experiment 1 was determined to be significant (Table 3-2 and 
Figures 3-1, 3-2). 
The response in SELE expression was large and observed to be statistically significant for every 
variant of TG2 added in at least one condition, including even the transglutaminase knockout 
C277A_Y315E (see Tables 3-8, 3-9, 3-10, 3-11, 3-12, and 3-13 and Figures 3-3, 3-4).  After 12 
hours of treatment, the increase in expression of SELE fell off dramatically, but remained elevated 
relative to buffer.   After 3 hours of treatment, and in some cases 12 hours, the mean relative 
expression level of SELE increased by a very large amount in both experiments in response to 
TNF-α, Y315E_L508W, and even transglutaminase knockout C277A_Y315E, but again, were 
deemed statistically insignificant due to large errors.   
In order to compare the relative expression levels of SELE among TG2 variants, I focused on 
experiment 2 and limited the number of pairwise comparisons to 6, so that the Bonferroni correction 
became less restrictive (Figure 3-11, Table 3-17).  When restricted to the pairwise comparisons 
among closed stabilized L312Y_F316T and L312Y, WT TG2, and open-locked Y315E_L508W, all 
comparisons were statistically significant save between L312Y and Y315E_L508W.  All three 
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designs exhibited a larger normalized expression levels than WT.  Among WT and the closed 
designs, increases in SELE expression correlated with increasing transglutaminase activity, with 
WT having the lowest level of expression and L312Y the highest (Table 3-8b).  Surprisingly, 
Y315E_L508W, with the lowest transglutaminase activity and highest GTPase activity in vitro had 
the highest mean level of expression of all four variants, although the difference between L312Y 
and Y315E_L508W was statistically insignificant. 
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Discussion 
The purpose of this study was to investigate perturbations arising in gene expression levels of 
targets previously found to be associated with celiac disease or the addition of celiac anti-TG2 
antibodies in response to the addition of conformationaly distinct forms of TG2 with differing levels 
of transglutaminase activity.  NFKB1A expression, which correlates with NF-κB activation, and E-
selectin expression, exhibited consistent and statistically significant up-regulation.  RHOB, FN1, 
and ITGB1, whose expression has previously been shown to be affected by CD antibodies, showed 
no statistically significant responses.  
NF-κB is a transcriptional regulator critical in the inflammatory response that can be activated by 
TG2, and in a positive-feedback loop, can induce the expression of TG2 [31, 33, 35, 44].  NF-κB is 
activated in the celiac gut [30], and celiac patients exhibit an increase in TG2 expression and 
transglutaminase activity [45, 46].  Studies have indicated that the binding of celiac antibodies to 
closed TG2 may be stabilizing a more active form of the enzyme, resulting in an increase in 
transglutaminase activity [17, 19, 26, 27].  We hypothesized that such an increase in 
transglutaminase activity could be a source of the induction of NF-κB activation in celiac disease, 
and therefore, this study investigated whether conformationaly distinct forms of TG2 with 
increasing levels of transglutaminase activity could induce increasing levels of NF-κB activity when 
added to the media of cultured HUVECs.  NF-κB activation was quantitated by measuring the 
expression of the IκB-α inhibitory subunit (NFKB1A), which is expressed in response to NF-κB 
activation [43].    
The modest increases in NFKB1A expression in response to the most transgltuaminase active 
designs (closed-biased L312Y and 312Y_F316T) indicate that activation of NF-κB may be 
occurring in response to higher extracellular levels of TG2 and/or transglutmainase activity.  
At this point, however, we are unable to conclude that increased transglutaminase activity or the 
closed conformation of TG2 are solely responsible for any possible increases in NF-κB activity, due 
to observed increases in the mean relative expression of NFKB1A in response to the 
transglutaminase knockout C277A_Y315E, and the transglutaminase knock-down and open-locked 
Y315E_L508W, although these data have large errors, rendering them statistically insignificant.   
It is not entirely unexpected that TG2 variants with little to no transglutaminase activity would elicit 
NF-κB activation given that the overexpression of C277S TG2, another transglutaminase knockout, 
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has been shown to elicit a similar level of NF-κB activation to that elicited by WT TG2 when 
overexpressed in mammary epithelial cells [41].  However, the result remains confusing since 
inhibiting transglutaminase activity has been shown to inhibit NF-κB activation [31, 32].  
Therefore, further investigation by traditional means of measuring NF-κB activation, such as an 
electrophoretic mobility shift assay, are warranted and should include TG2 variants with decreased 
or eliminated transglutaminase activity, as well as celiac anti-TG2 autoantibodies.  Such traditional 
means of measuring NF-κB activation may give more precise results. 
During the inflammatory response in celiac disease, lymphocyctes adhere to the vascular 
endothelium as they migrate to the sites of chronic inflammation in the lamina propria of the small 
intestine [17, 23].  Integral to lymphocytes’ ability to bind the endothelium are adhesion molecules, 
which are up-regulated in celiac disease [23-25].  E-selectin is one such adhesion molecule whose 
levels in the sera of celiac patients have been found to be more than 10-fold higher than the levels in 
healthy controls [24].  One study showed that celiac IgA induces the up-regulation in expression of 
E-selectin, whereas non-celiac IgA did not [17].   
As mentioned above, evidence suggests that celiac anti-TG2 autoantibodies may be binding the 
closed-conformation of TG2, possibly stabilizing a more transglutaminase-active form of the 
enzyme, suggesting that this increased activity may be the source of the pathogenic effects derived 
from these antibodies [17, 19, 26, 27].  If this hypothesis were true, we expected the closed-biased, 
more transglutaminase active variants of TG2 (L312Y and L312Y_F316T) to result in the largest 
increase in E-selectin (SELE) expression, whereas the less active open-locked Y315E_L508W was 
expected to yield the lowest increase in SELE expression. 
In experiment 2, the relative expression levels of SELE among WT and closed-biased 
L312Y_F316T and L312Y did increase with increasing transglutaminase activity: (1) WT, TGase 
Vmax 1.6 FI/s, 101-fold increase in SELE expression relative to untreated, (2) closed-biased 
L312Y_F316T, Vmax 1.8 FI/s, 146-fold increase, (3) closed-biased L312Y, Vmax 2.0 FI/s, 230-fold 
increase (See chapter 2 and table 3-8b).   This indicates that greater levels of transglutaminase 
activity may lead to more SELE expression and therefore greater anti-angiogenic effects.   
However, variants with little to no transglutaminase activity still yielded large increases in SELE 
expression in both experiments.  Open-locked Y315E_L508W, with a transglutaminase Vmax of 0.47 
FI/s gave the largest fold increase in SELE (404-fold) in experiment 2, similar to what was 
observed upon treatment with TNF-α, a known inducer of SELE expression [36].  Transglutaminase 
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knockout and open-locked C277A_Y315E also yielded large increases in SELE expression in both 
experiments, although when the Bonferroni correction for 21 comparisons were made, this increase 
was determined to be statistically significant for only one condition (see Tables 3-8 through 3-13 
and Figures 3-3 and 3-4).  These results cast serious doubt on the hypothesis that increased 
transglutaminase activity alone is the cause of the pathogenic effects observed.  Extracellular TG2 
has been shown to activate various pathways by both transglutaminase dependent [47] and 
independent mechanisms [48, 49], and our results indicate that the open conformation itself may be 
conducive to a binding event that induces SELE expression via some unknown pathway.  Also of 
note is that Y315E_L508W exhibits the largest GTPase activity of all the designs added, although 
C277A_Y315E’s GTPase activity is unknown.  If this increase in GTPase results from the adoption 
of the open conformation, this activity may also have some unknown effect on SELE expression. 
TG2 has previously been reported to activate NF-κB [33-35], and TNF-α, a cytokine involved in the 
immune and inflammatory responses which also activates NF-κB, has also been shown to up-
regulate E-selectin [36, 37].   E-selectin expression also has been reported to be induced by NF-κB 
binding to E-selectin’s regulatory elements [50].  Another study demonstrated that celiac anti-TG2 
antibodies could induce NF-κB activity by binding Toll-like receptor 4 (TLR4) in 293T cells [51].  
Perhaps the increase in E-selectin resulting from the addition of CD anti-TG2 antibodies results 
from up-regulation via NF-κB activation mediated by the binding of CD antibodies to TLR4, and 
adding TG2 to the media can bring about a similar effect by activating NF-κB.  As mentioned in the 
introduction, the mechanism by which increased amounts of TG2 can induce NF-κB are not yet 
fully understood, and may be independent of transglutaminase activity.   
An interesting follow-up study would be to repeat the experiment, but block NF-κB activation and 
look to see if this blocks any up-regulation in E-selectin expression in response to the addition of 
TG2.  If the observed increase in E-selectin expression in this study in response to transglutaminase 
active variants is decreased in the repeated experiment in cells with blocked NF-κB activation, but 
still elevated relative to untreated cells, this could indicate that increased transglutaminase activity 
could still contribute to the pathogenic effects induced by celiac autoantibodies, but by a separate 
pathway.  This hypothesis would further be supported if E-selectin expression were unchanged in 
cells treated with transgltuaminase knockouts when NF-κB activation is blocked.  This method 
would only work, however, if the proposed effects induced by increasing transglutaminase activity 
do not rely upon NF-κB activation as well.  
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Additionally, another type of assay may be beneficial to look at the anti-angiogenic effects of 
various TG2 designs compared to CD antibodies.  One option is the tubule-length formation assay 
in HUVECs, where decreased tubule length formation is an indication of inhibited angiogenesis.  
This assay could be illuminating because studies showed that reduced tubule formation in response 
to anti-TG2 antibodies could be reversed by the addition of transglutaminase inhibitors [17, 19]. 
The possibility exists that simply adding TG2 to the media of HUVECs does not correctly mimic 
the events that occur when CD anti-TG2 antibodies bind extracellular TG2 associated with other 
proteins on the surface of the cell, and that the addition of TG2 to the media only activated NF-κB, 
and therefore increased E-selectin, via the positive feedback loop between TG2 and NF-κB.  Also, 
although celiac autoantibodies were found to increase transgltuaminase activity in culture, the TG2 
added to the media of HUVECs may not be active, although previous studies have shown that 
exogenous TG2 added to HUVEC media retained transglutaminase activity [42].  The stability of 
TG2 in the media of HUVECs is also unknown, and any increase in TG2 activity might be fleeting 
and therefore insufficient to elicit a response when compared to that of TG2 associated with the 
membrane of cells, or antibodies associated with endogenous TG2.  This could explain why 
statistically significant responses in FN1, ITGB1, and RHOB expression were not observed.  
Repeated addition of TG2 variants to the cells, similar to the method used in [42], may be able to 
overcome short TG2 lifetimes in the media.  Measuring the amount of endogenous in situ TG2 
activity via fluorescein cadaverine incorporation as preformed in [42] would be useful in confirming 
and quantifying relative amounts of TG2 activity and the lifetime of the enzyme.  It is also possible 
that increased transglutaminase activity plays no role in the pathogenic effects of celiac antibodies, 
but this is doubtful considering results that found that the anti-angiogenic and increased lymphocyte 
adhesion and transendothelial migration effects of CD antibodies could be reversed by the addition 
of transglutaminase inhibitors [17, 19], although the control of inhibitor alone added to cells was not 
conducted.  
Knock-down of endogenous TG2 and transfection and expression of designs in HUVECs represents 
an alternative means to investigate the effects of differing levels of activity of TG2 on gene 
expression, but may be undesirable since TG2 is involved in GTPase signal transduction 
intracellularly, and therefore may alter the internal biology of the cell.  This is especially relevant 
given the dramatic differences in GTPase activity observed among the TG2 designs.  The open-
locked variant used in this study (Y315E_L508W) has a much higher GTPase activity than WT or 
the two closed-biased designs studied here (see Chapter 2), therefore it would be interesting to test 
the GTPase activities of other open-locked designs to attempt to find one whose GTPase activity is 
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not that different than WT.  This may not be possible given the potential for the conformation to be 
the source of the increase in GTPase activity.  However, even if an open-locked TG2 with similar 
GTPase activity to WT can be designed to negate this inequality, a second undesirable complication 
arises from the potential for the change in conformational preference to interfere with TG2’s 
interactions with other proteins.  Due to these concerns, and because the effects of celiac anti-TG2 
antibodies are believed to be mediated solely by their binding to extracellular TG2, we chose to 
simply add the designs to the cell media in this study. 
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Conclusions 
In summary, the addition of all design variants of TG2 to HUVEC culture did increase NFKB1A 
and especially E-selectin expression.  Because TG2 also has been shown to induce NF-κB 
activation via a pathway that may be independent of transglutaminase activity, it is possible that 
addition of TG2 to the media may bring about NF-κB activation, and the associated up-regulation of 
E-selectin.  Therefore, future experiments should attempt to isolate the effects of transglutaminase 
activity by blocking NF-κB activation.  The increases in E-selectin expression were strong, fleeting, 
and for closed-biased and WT TG2, correlated with transglutaminase activity, indicating that 
increased transglutaminase activity may be pathogenic.  This finding supports the hypothesis that 
the stabilization of the closed form of TG2 may increase transglutaminase activity, and this may 
cause pathogenic effects.  However, the transglutaminase knock-down and knockout variants 
induced at times even larger increased in E-selectin expression, which in some cases was 
indistinguishable from TNF-α-induced E-selectin up-regulation.  These two variants adopt the open 
conformation, and it is possible that this conformation or a possible increase in GTPase activity, and 
not transglutaminase activity, may contribute to the effects observed in some unknown way. 
In addition to conducting the tubule-formation assay to compare the responses of live cells to 
various levels of transglutaminase activity and conformation, we believe a fuller picture of the cell’s 
state after exposure to our variants is warranted.  Because E-selectin gene expression and NF-κB 
activation were increased in this study as a response to our TG2 variants by mechanisms that are not 
fully understood, we believe that this experiment should be repeated and RNA-Seq conducted to 
profile the transcriptome in response to various TG2 designs.  The results from such a study may be 
able to indicate if the different designs are activating different pathways or help determine the 
mechanism by which we see these changes in expression and activation. 
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Tables and Figures 
Table 3-1.  List of primers for qPCR analysis. 
Gene Primer Direction Sequence 
GAPDH F 5'-TGTAGTTGAGGTCAATGAAGGG-3' 
 
R 5'-ACATCGCTCAGACACCATG-3' 
SDHA F 5'-CTGCCCCTTGTAGTTGGTG-3' 
 
R 5'-GTGGACGTCACGAAGGAG-3' 
TBP F 5'-TCGTGGCTCTCTTATCCTCAT-3' 
 
R 5'-CAGTGAATCTTGGTTGTAAACTTGA-3' 
RHOB F 5'-GGTTTCTTTTCCCTCTCCTTGT-3' 
 
R 5'-GCACTCGTCATTTGCATACG-3' 
SELE F 5'-TGTAGCTGAAGTTTCCCAGTG-3' 
 
R 5'-CTGGCTTCAGTGGACTCAA-3' 
ITGB1 F 5'-GGTCAATGGGATAGTCTTCAGC-3' 
 
R 5'-GTAGCAAAGGAACAGCAGAGA-3' 
NFKBIA F 5'-GAGTCAGAGTTCACGGAGTTC-3' 
 
R 5'-CATGTTCTTTCAGCCCCTTTG-3' 
FN1 F 5'-GTCCTTGTGTCCTGATCGTTG-3' 
  R 5'-AGGCTGGATGATGGTAGATTG-3' 
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Table 3-2.  Normalized expression of NFKB1A under different treatment conditions after 3, 12 and 
24 hours’ exposure, with standard error of means. (A) Experiment 1.  (B) Experiment 2.  Values are 
relative to untreated cells. 
A 3 hours 12 hours 24 hours 
Buffer 0.813 ± 0.0250 0.860 ± 0.0959 1.22 ± 0.120 
TNFα 10.5 ± 1.42 6.67 ± 0.124 4.95 ± 0.774 
C277A Y315E 5.85 ± 0.345 3.73 ± 0.0864 2.68 ± 0.193 
Y315E L508W 8.14 ± 2.19 3.11 ± 0.218 1.82 ± 0.441 
WT 3.71 ± 0.243 2.36 ± 0.0689 2.65 ± 0.302 
L312Y F316T 3.87 ± 0.089 2.62 ± 0.139 2.61 ± 0.199 
L312Y 5.12 ± 0.220 2.94 ± 0.825 2.94 ± 0.217 
 
B 3 hours 12 hours 24 hours 
Buffer 0.847 ± 0.103 1.07 ± 0.100 1.34 ± 0.014 
TNFα 9.31 ± 2.82  7.56 ± 1.22 9.12 ± 0.587 
C277A Y315E 4.19 ± 3.45 4.48 ± 0.273 3.94 ± 0.632 
Y315E L508W 6.86 ± 0.441 4.26 ± 0.292 3.76 ± 0.200 
WT 3.99 ± 0.176  2.13 ± 0.270 3.25 ± 0.093 
L312Y F316T 4.47 ± 0.0983 3.24 ± 0.0864 3.21 ± 0.046 
L312Y 5.03 ± 0.102 4.44 ± 0.0886 3.52 ± 0.744 
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Figure 3-1.  Normalized relative expression of NFKB1A in HUVECs treated with indicated 
proteins for 3 hours [52], 12 hours (blue), or 24 hours (green) in experiment 1 (Invitrogen).  Values 
are relative to untreated cells, error bars indicate standard error of means. 
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Table 3-3.  Matrix of relative differences in NFKB1A expression determined to be significant after 
3 hours of treatment in experiment 1 using the Bonferroni correction where the p<0.05 was 
considered significant. 
Buffer               
TNFα               
C277A 
Y315E             
 Y315E 
L508W               
WT               
L312Y 
F316T             X 
L312Y             
 NFKB1 
1_3hr L312Y 
L312Y 
F316T WT 
Y315E 
L508W 
C277A 
Y315E TNFα Buffer 
 
Table 3-4.  Matrix of relative differences in NFKB1A expression determined to be significant after 
12 hours of treatment in experiment 1 using the Bonferroni correction where the p<0.05 was 
considered significant. 
Buffer               
TNFα             X 
C277A 
Y315E           
  Y315E 
L508W           
 
  
WT           X   
L312Y 
F316T           
 
  
L312Y               
NFKB1 
1_12hr L312Y 
L312Y 
F316T WT 
Y315E 
L508W 
C277A 
Y315E TNFα Buffer 
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Figure 3-2.  Normalized relative expression of NFKB1A in HUVECs treated with indicated 
proteins for 3 hours [52], 12 hours (blue), or 24 hours (green) in experiment 2 (Lonza).  Values are 
relative to untreated cells, error bars indicate standard error of means. 
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Table 3-5.  Matrix of relative differences in NFKB1A expression determined to be significant after 
3 hours of treatment in experiment 2 using the Bonferroni correction where the p<0.05 was 
considered significant. 
Buffer               
TNFα               
C277A 
Y315E               
Y315E 
L508W               
WT             
 L312Y 
F316T             X 
L312Y             X 
NFKB1A 
2_3hr L312Y 
L312Y 
F316T WT 
Y315E 
L508W 
C277A 
Y315E TNFα Buffer 
 
Table 3-6.  Matrix of relative differences in NFKB1A expression determined to be significant after 
12 hours of treatment in experiment 2 using the Bonferroni correction where the p<0.05 was 
considered significant. 
Buffer               
TNFα               
C277A 
Y315E               
Y315E 
L508W               
WT               
L312Y 
F316T             
 L312Y             X 
NFKB1A 
2_12hr L312Y 
L312Y 
F316T WT 
Y315E 
L508W 
C277A 
Y315E TNFα Buffer 
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Table 3-7.  Matrix of relative differences in NFKB1A expression determined to be significant after 
24 hours of treatment in experiment 2 using the Bonferroni correction where the p<0.05 was 
considered significant. 
Buffer               
TNFα               
C277A 
Y315E               
Y315E 
L508W               
WT             
 L312Y 
F316T             X 
L312Y               
NFKB1A 
2_24hr L312Y 
L312Y 
F316T WT 
Y315E 
L508W 
C277A 
Y315E TNFα Buffer 
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Table 3-8.  Normalized expression of SELE under different treatment conditions after 3, 12 and 24 
hours’ exposure, with standard error of means. (A) Experiment 1.  (B) Experiment 2.  Values are 
relative to untreated cells. 
A 3 hours 12 hours 24 hours 
Buffer 0.861 ± 0.0537 1.25 ± 0.143 1.85 ± 0.123 
TNFα 245 ± 33.7 150 ± 8.15 91.3 ± 5.69 
C277A Y315E 164 ± 9.65 13.3 ± 0.356 3.05 ± 0.0977 
Y315E L508W 287 ± 67.4 11.7 ± 1.69 2.84 ± 0.0903 
WT 55.4 ± 4.18 8.29 ± 0.288 4.80 ± 0.545 
L312Y F316T 63.5 ± 1.94 12.9 ± 1.35 4.73 ± 0.413 
L312Y 119 ± 1.67 12.4 ± 2.47 2.34 ± 0.188 
 
B 3 hours 12 hours 24 hours 
Buffer 0.588 ± 0.155 1.13 ± 0.241 2.24 ± 0.0231 
TNFα 386 ± 39.3 413 ± 28.9 130 ± 24.1 
C277A Y315E 95.9 ± 15.9 32.7 ± 1.96 9.61 ± 0.986 
Y315E L508W 404 ± 24.4 21.1 ± 0.548 5.70 ± 0.235 
WT 101 ± 2.77 14.4 ±  1.74 6.45 ± 0.175 
L312Y F316T 146 ± 3.18 16.6 ± 0.0742 7.63 ± 0.111 
L312Y 230 ± 6.26 17.4 ± 0.177 5.24 ± 1.88 
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Figure 3-3.  Normalized relative expression of SELE in HUVECs treated with indicated proteins for 
3 hours [52], 12 hours (blue), or 24 hours (green) in experiment 1 (Invitrogen).  Values are relative 
to untreated cells, error bars indicate standard error of means. 
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Table 3-9.  Matrix of relative differences in SELE expression determined to be significant after 3 
hours of treatment in experiment 1 using the Bonferroni correction where the p<0.05 was 
considered significant. 
Buffer               
TNFα               
C277A 
Y315E             
 Y315E 
L508W               
WT               
L312Y 
F316T             X 
L312Y   
  
       X 
SELE 
1_3hr L312Y 
L312Y 
F316T WT 
Y315E 
L508W 
C277A 
Y315E TNFα Buffer 
 
Table 3-10.  Matrix of relative differences in SELE expression determined to be significant after 12 
hours of treatment in experiment 1 using the Bonferroni correction where the p<0.05 was 
considered significant. 
Buffer               
TNFα             
 C277A 
Y315E           
 
X 
Y315E 
L508W           
 
  
WT           
  L312Y 
F316T           
 
  
L312Y           
 
  
SELE 
1_12hr L312Y 
L312Y 
F316T WT 
Y315E 
L508W 
C277A 
Y315E TNFα Buffer 
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Figure 3-4.  Normalized relative expression of SELE in HUVECs treated with indicated proteins for 
3 hours [52], 12 hours (blue), or 24 hours (green) in experiment 2 (Lonza).  Values are relative to 
untreated cells, error bars indicate standard error of means. 
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Table 3-11.  Matrix of relative differences in SELE expression determined to be significant after 3 
hours of treatment in experiment 2 using the Bonferroni correction where the p<0.05 was 
considered significant. 
Buffer               
TNFα               
C277A 
Y315E               
Y315E 
L508W             
 WT             X 
L312Y 
F316T             X 
L312Y     
 
      X 
SELE 
2_3hr L312Y 
L312Y 
F316T WT 
Y315E 
L508W 
C277A 
Y315E TNFα Buffer 
 
Table 3-12.  Matrix of relative differences in SELE expression determined to be significant after 12 
hours of treatment in experiment 2 using the Bonferroni correction where the p<0.05 was 
considered significant. 
Buffer               
TNFα             
 C277A 
Y315E             
 Y315E 
L508W             X 
WT               
L312Y 
F316T             X 
L312Y             X 
SELE 
2_12hr L312Y 
L312Y 
F316T WT 
Y315E 
L508W 
C277A 
Y315E TNFα Buffer 
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Table 3-13.  Matrix of relative differences in SELE expression determined to be significant after 24 
hours of treatment in experiment 2 using the Bonferroni correction where the p<0.05 was 
considered significant. 
Buffer               
TNFα               
C277A 
Y315E               
Y315E 
L508W             
 WT             X 
L312Y 
F316T             X 
L312Y               
SELE 
2_24hr L312Y 
L312Y 
F316T WT 
Y315E 
L508W 
C277A 
Y315E TNFα Buffer 
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Table 3-14.  Normalized expression of RHOB under different treatment conditions after 3, 12 and 
24 hours’ exposure, with standard error of means. (A) Experiment 1.  (B) Experiment 2.  Values are 
relative to untreated cells. 
A 3 hours 12 hours 24 hours 
Buffer 1.02 ± 0.0208 1.15 ± 0.161 1.03 ± 0.0720 
TNFα 2.46 ± 0.192 1.87 ± 0.0569 1.36 ± 0.303 
C277A Y315E 1.80 ± 0.0401 1.45 ± 0.0430 1.23 ± 0.0539 
Y315E L508W 2.39 ± 0.396 1.40 ± 0.166 1.40 ± 0.0309 
WT 1.49 ± 0.0961 1.21 ± 0.0114 1.44 ± 0.180 
L312Y F316T 1.37 ± 0.0315 1.21 ± 0.0811  1.41 ± 0.0930 
L312Y 1.68 ± 0.0376 1.25 ± 0.332 1.42 ± 0.107 
 
B 3 hours 12 hours 24 hours 
Buffer 0.921 ± 0.262  1.03 ± 0.0364 1.15 ± 0.0217 
TNFα 2.19 ± 0.243 1.82 ± 0.185 2.29 ± 0.273 
C277A Y315E 1.94 ± 0.361 1.35 ± 0.0658 1.46 ± 0.137 
Y315E L508W 1.87 ± 0.0595 1.41 ± 0.0192 1.55 ± 0.153  
WT 1.45 ± 0.0559 1.64 ± 0.220 1.49 ± 0.036 
L312Y F316T 1.61 ± 0.0841 1.29 ± 0.0259 1.33 ± 0.120 
L312Y 1.55 ± 0.0544 1.43 ± 0.0904 1.26 ± 0.321 
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Figure 3-5.  Normalized relative expression of RHOB in HUVECs treated with indicated proteins 
for 3 hours [52], 12 hours (blue), or 24 hours (green) in experiment 1 (Invitrogen).  Values are 
relative to untreated cells, error bars indicate standard error of means. 
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Figure 3-6.  Normalized relative expression of RHOB in HUVECs treated with indicated proteins 
for 3 hours [52], 12 hours (blue), or 24 hours (green) in experiment 2 (Lonza).  Values are relative 
to untreated cells, error bars indicate standard error of means. 
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Table 3-15.  Normalized expression of ITGB1 under different treatment conditions after 3, 12 and 
24 hours’ exposure, with standard error of means. (A) Experiment 1.  (B) Experiment 2.  Values are 
relative to untreated cells. 
A 3 hours 12 hours 24 hours 
Buffer 1.05 ± 0.0295 0.997 ± 0.111 1.25 ± 0.0833 
TNFα 0.360 ± 0.0522 1.19 ± 0.0248 1.16 ± 0.0582 
C277A Y315E 1.09 ± 0.0244 1.26 ± 0.0321 1.41 ± 0.0313 
Y315E L508W 1.12 ± 0.141 1.07 ± 0.0772 1.59 ± 0.0369 
WT 1.07 ± 0.0529 1.11 ± 0.00972 1.65 ± 0.191 
L312Y F316T 0.818 ± 0.146 1.27 ± 0.0466 0.708 ± 0.0566 
L312Y 1.07 ± 0.0186 1.26 ± 0.159 1.55 ± 0.115 
 
A 3 hours 12 hours 24 hours 
Buffer 0.833 ± 0.134  0.867 ± 0.0672 0.932 ± 0.0135 
TNFα 0.608 ± 0.0593 0.959 ± 0.0555 1.09 ± 0.135 
C277A Y315E 0.494 ± 0.0940 1.07 ± 0.0622 1.13 ± 0.0947 
Y315E L508W 0.928 ± 0.0414 1.07 ± 0.0136 1.17 ± 0.0630 
WT 0.876 ± 0.0427 0.763 ± 0.0889 1.02 ± 0.0333 
L312Y F316T 0.925 ± 0.0370 0.955 ± 0.00399 1.01 ± 0.0230 
L312Y 0.885 ± 0.0422 0.992 ± 0.00541 0.723 ± 0.0671 
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Figure 3-7.  Normalized relative expression of ITGB1 in HUVECs treated with indicated proteins 
for 3 hours [52], 12 hours (blue), or 24 hours (green) in experiment 1 (Invitrogen).  Values are 
relative to untreated cells, error bars indicate standard error of means. 
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Figure 3-8.  Normalized relative expression of ITGB1 in HUVECs treated with indicated proteins 
for 3 hours [52], 12 hours (blue), or 24 hours (green) in experiment 2 (Lonza).  Values are relative 
to untreated cells, error bars indicate standard error of means. 
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Table 3-16.  Normalized expression of FN1 under different treatment conditions after 3, 12 and 24 
hours’ exposure, with standard error of means. (A) Experiment 1.  (B) Experiment 2.  Values are 
relative to untreated cells. 
A 3 hours 12 hours 24 hours 
Buffer 0.803 ± 0.0161 0.799 ± 0.0871 1.04 ± 0.0609 
TNFα 0.755 ± 0.0574 0.892 ± 0.0330 0.973 ± 0.0409 
C277A Y315E 1.04 ± 0.0615 0.938 ± 0.0147 1.04 ± 0.0381 
Y315E L508W 0.986 ± 0.128 0.832 ± 0.0463 1.33 ± 0.0680 
WT 0.944 ± 0.0414 0.970 ± 0.0292 1.26 ± 0.160 
L312Y F316T 1.01 ± 0.0402 0.960 ± 0.0358 1.30 ± 0.0816 
L312Y 1.03 ± 0.0253 1.06 ± 0.161 1.39 ± 0.115 
 
A 3 hours 12 hours 24 hours 
Buffer 0.966 ± 0.170 1.28 ± 0.0879 1.30 ± 0.0415 
TNFα 0.813 ± 0.0805 1.04 ± 0.101 1.22 ± 0.141 
C277A Y315E 0.571 ± 0.133 1.10 ± 0.0561  1.19 ± 0.152 
Y315E L508W 1.40 ± 0.0787 1.10 ± 0.0753 1.56 ± 0.0370 
WT 1.27 ± 0.0646 0.960 ± 0.117 1.47 ± 0.110 
L312Y F316T 1.39 ± 0.0542 1.15 ± 0.0172 1.40 ± 0.0179 
L312Y 1.28 ± 0.0252 1.18 ± 0.0529 0.889 ± 0.101 
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Figure 3-9.  Normalized relative expression of FN1 in HUVECs treated with indicated proteins for 
3 hours [52], 12 hours (blue), or 24 hours (green) in experiment 1 (Invitrogen).  Values are relative 
to untreated cells, error bars indicate standard error of means. 
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Figure 3-10.  Normalized relative expression of FN1 in HUVECs treated with indicated proteins for 
3 hours [52], 12 hours (blue), or 24 hours (green) in experiment 2 (Lonza).  Values are relative to 
untreated cells, error bars indicate standard error of means. 
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Figure 3-11.  Normalized relative expression of SELE in HUVECs after 3 hours of treatment with 
the indicated variant of TG2 in experiment 2.  Values are relative to untreated cells.   
Table 3-17.  Matrix of the pairwise comparisons of relative differences in SELE expression 
determined to be statistically significant in experiment 2 when limited to the three designs indicated 
and WT TG2. 
Y315E L508W         
WT X       
L312Y F316T X X     
L312Y   X X   
  Y315E L508W WT L312Y F316T L312Y 
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A p p e n d i x  A  
SITE-SATURATION MUTAGENESIS OF THE ACTIVE SITE OF A  
DEISGNED KEMP ELIMINATION ENZYME 
 
Abstract 
Enzymes are biological super catalysts.  They are highly specific, can function at biological pH and 
temperature, and accelerate reactions with rate enhancements of 105–1017.  Enzymes have practical 
applications as medicinal therapeutics and as catalysts for industrial processes, but enzymes 
available for such uses have historically been limited to what is found in nature.  Therefore, the de 
novo design of enzymes with novel activities has become a major scientific goal.  Previous work in 
the Mayo lab resulted in the successful design of a de novo enzyme catalyzing the Kemp 
elimination: HG2/S265T.  This enzyme was designed using the protein design software PHOENIX 
and molecular dynamics (MD) simulations, and has a kcat/Km of 430 M−1s−1.  Although quite an 
accomplishment, this value is still far lower than the 107 M−1s−1 values typically found in nature.  To 
further increase the activity of this enzyme and to identify weaknesses in our computational design 
methods, we performed site-saturation mutagenesis on the active site of HG2/S265T. The resulting 
209 mutants were expressed and screened for Kemp elimination activity.  Of the 209 mutants 
screened, 22 were exhibited higher activity than WT protein.  After purification and kinetic 
characterization, four were found to be more active than HG2/S265T: K50M, M172I, M84I, and 
K50Q.  K50M saw the largest overall increase in activity, with a kcat/Km of 2.5 x 103.  Using these 
results to optimize our design parameters so that the predictions made by our computational 
methods better match that which is observed in vitro will improve our model, furthering our long 
term goal of designing de novo enzymes with kcat/Km values closer to those found in nature. 
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Introduction 
Enzymes 
All living organisms must be able to self-replicate and selectively catalyze chemical reactions.  
Biological systems employ enzymes, which are usually specialized proteins, as catalysts for their 
necessary reactions (the exception being catalytic RNA molecules).  Enzymes are far superior to 
synthetic and inorganic catalysts: they bind their substrates with high specificity, function in an 
aqueous environment (often under mild pH and temperature conditions), and accelerate chemical 
reactions several orders of magnitude (rate enhancements typically range from 105 to 1017) [1]. 
Enzymes are of practical interest in medicine and industry.  Many diseases are caused by the lack of 
a necessary enzyme or by some aberrant enzymatic activity. Consequently, enzymes or molecules 
that inhibit them are often used as therapeutics.  The special properties of these molecules also make 
them very attractive in the chemical industry.  Their high specificity, ability to yield products of a 
single enantiomer, activity at low temperatures, and impressive rate enhancements make enzymes 
much more cost effective than inorganic and synthetic catalysts, which often require extreme 
temperatures to accelerate reactions minimally and with low specificity. 
Enzymes available for use as drugs and to catalyze industrial processes have historically been 
limited to what can be found in nature.  Protein engineering has been used to improve the stability 
or specificity of natural enzymes, but the de novo design of enzymes with novel activities is much 
more challenging and has become a major scientific goal. 
 
Enzyme Design 
Early work to design a de novo enzyme focused on the Kemp elimination, not because it is an 
important reaction for industry or medicine, but because it is a well-characterized reaction with no 
natural protein catalyst and is a realistic first time de novo enzyme design goal [2-4].  The Kemp 
elimination is a simple reaction involving the base-catalyzed abstraction of a proton from the C3 
position of 5-nitrobenzisoxazole to yield 2-cyano-4-nitrophenolate (Figure A-1).  These design 
attempts were based on the work of Thorn et al., who created a catalytic Kemp elimination 
antibody, 34E3, by generating charge complementarity between an antibody and a benzimdazolium 
hapten.  34E3 has a kcat/Km of 5.5 × 103 M−1s−1 [5].  X-ray crystallography of 34E3 showed that 
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hydrogen bonding, π stacking, and van der Waals interactions positioned the substrate for catalysis.  
Specifically, the catalytic glutamate residue formed a bidentate salt bridge with the charged 
guanidinium group of the hapten substrate.  Also, the hapten was stacked between the sidechains of 
two aromatic residues, a tryptophan and a tyrosine [6]. 
 
Enzyme Design in the Mayo Lab 
Past work in the Mayo lab also focused on designing a de novo enzyme to catalyze the Kemp 
elimination [7].  To achieve this goal, a design strategy dubbed the protein design cycle was used.  
The design cycle consists of three main steps: (1) design, where protein sequences predicted to 
assume the desired three-dimensional structure are calculated using computational methods, (2) 
evaluation, where the sequences predicted by the design calculations are analyzed and tested both 
computationally and in vitro to see if they possess the desired characteristics, and (3) adjustment, 
where the results of the evaluations are used to modify the design procedure to garner improved 
results [7, 8]. 
Initial attempts at a de novo Kemp elimination enzyme produced HG1. This design was based on 
the scaffold 10A xylanase (TAX) and was performed using ORBIT, a computational protein design 
software program created in the Mayo lab.  Unfortunately, HG1 was inactive.  X-ray 
crystallography showed that the active site was very similar to the design; however, structural 
analysis and molecular dynamics (MD) simulations also indicated that the active site was flexible 
and very solvent exposed with many water molecules present.  To avoid these problems, future 
designs positioned the active site more deeply within the protein scaffold. 
A second round of design, this time using the design software PHOENIX (also developed in the 
Mayo lab), yielded HG2, with a kcat/Km of 122 M−1s−1.  The design for HG2 included a more buried 
catalytic aspartate at position 127, a tryptophan residue at position 265 to π stack with the substrate, 
a lysine at position 50 to interact with the substrate nitro group, and a serine at position 265 to 
hydrogen bond with the isoxazole oxygen (Figure A-2). MD simulations indicated that although 
S265 did not make the desired hydrogen bond contact to the substrate, the serine was preventing 
water from entering the active site by pushing the substrate closer to the base.  
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MD was also successful in predicting the catalytic activity of three additional designs in two 
alternate scaffolds, and subsequently became an integral part of our design procedure.  The mutant 
HG2/S265T was predicted to have improved activity by making the desired hydrogen bonding 
contact to the substrate and by creating better active site packing due to its larger size.  HG2/S265T 
was constructed and found to have a kcat/Km of 430 M−1s−1, three-fold higher than any Kemp 
elimination enzyme designed thus far [7, 9]. 
 
Site-Saturation Mutagenesis of the HG2 Active Site 
The following describes the site-saturation mutagenesis on the 11 residues surrounding the substrate 
in the active site of HG2.  Each of the 11 residues was mutated to every other possible amino acid 
iteratively, resulting in a total of 209 mutants.  These mutants were screened for Kemp elimination 
activity.  The purpose of this experiment is two-fold.  First, we hope to improve HG2’s activity by 
discovering which mutations will result in a better enzyme.  Secondly, these results will inform us 
as to how well our computational methods are able to accurately predict the optimal sequence or the 
outcome of a mutation for this design.  In particular, these data will be used as a stringent screen of 
an MD protocol being developed in the Mayo lab to predict the activity of all 209 mutants that will 
be produced.  Design parameters will then be optimized to reduce any disagreement between what 
is predicted and what is observed. 
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Methods 
Choosing Active Site Residues for Mutagenesis 
Active site residues were selected for mutagenesis by examining the active site of the HG-2 design.  
Every residue surrounding the transition state of the 5-nitrobenzoxizole Kemp elimination reaction 
(NBX) in the design was chosen for mutagenesis.  Eleven residues were chosen in all: Ala21, 
Met42, Glu46, Met84, Met172, Met237, and Leu236, as well as those interacting with the substrate: 
Trp44, Lys50, Asp127, and Ser265 (or Thr265) (Figures A-3a and b).   
 
Megaprimed Site-Directed Mutagenesis 
Site-directed mutagenesis was performed using the megaprimed, ligase-free, PCR-based, site-
directed mutagenesis method described in Tseng et al. [10].  This method is specialized for high-
throughput mutagenesis because it only requires one mutagenic primer.  For each mutant, one 
mutagenic forward primer and one universal flanking primer are used in an initial amplification 
reaction to generate complementary megaprimers that are then used to amplify the mutated plasmid 
as one would in a typical QuikChange reaction (Stratagene).  The melting temperatures of the 
mutagenic forward primers were calculated using the equation: 
Tm = 81.5 + 0.41(%GC) - 675/N - %mismatch    (1) 
For the majority of the mutants, the generation of megaprimers followed by the amplification of 
mutated template was performed in a single reaction.  PCR mixtures contained 25 µL 22 ng of 
template HG2/S265T in pET11a (Novagen), 100 nM of each primer, 200 µM of each 
deoxymucleotide triphosphate (dNTP), 1.25 U of PfuTurbo DNA polymerase, and PfuTurbo DNA 
polymerase buffer (Stratagene). The PCR program consisted of 95°C for 5 min; 18 cycles to 
generate megaprimer consisting of 95°C for 1 min, 60°C for 1 min, and 68°C for 2 min.  
Amplification of mutated template was then achieved by 18 cycles of 95°C for 1 min and 68°C for 
20 min; a final extension at 68°C for 10 min completed the reaction. 
Generation of megaprimers and amplification of mutated template was verified via agarose gel 
electrophoresis.  If a reaction yielded megaprimer but failed to amplify template, a second reaction 
was run using the same mixture components as above except the primers were replaced by 1.25 µl 
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of the PCR products from the initial reaction.  The PCR was then run under the following 
conditions: 95°C for 5 min; 18 cycles of 95°C for 1 min and 68°C for 20 min; and a final extension 
at 68°C for 10 min.   
Upon completion of the PCR reactions, 3.5 µl of 10x NEBuffer 4, 3.18 µl Diluent Buffer B, and 
66.4 U (3.32 µl) of DpnI (New England Biolabs) were added to each reaction mixture and incubated 
at 37°C for 2 hours.   
 
Transformation and Plating 
Transformation and plating were performed using a Tecan Freedom EVO liquid handling robot by 
dividing the mutagenic primers over three 96-well plates.  Mutagenesis and transformation was 
performed on one plate at a time.  PCR reactions were transferred to 96-well PCR plates and 2 µl of 
each reaction was transformed into 20 µl of BL21 DE3 chemically competent cells by heatshock at 
42°C for 45 sec in the robot thermocycler.  100 µl of LB (Luria-Bertani broth) was then added to 
each reaction, and the cultures were shaken at 1800 rpm in 30-sec intervals for 2 hours to keep cells 
suspended. 
Cells were then plated onto 48 well LB/agar ampicillin qtrays and allowed to grow overnight at 
37°C.  Two colonies were picked for each mutant and grown for 14 hours at 37°C in 200 µl of 
LB/ampicillin with 10% glycerol in 96-well culture plates. 
The plates were replicated into glycerol stocks, and the original culture plate was sent to Agencourt 
Biosciences for off-site mini-prepping and sequencing.  If both colonies yielded wild-type 
sequences or undesired mutations, another colony from that mutant’s well was picked, mini-
prepped (Qiagen), and sequenced.  If this attempt still yielded the incorrect sequence, or if no 
colonies had grown in the first place, the mutagenesis procedure was repeated for that mutant along 
with the next plate of mutants. 
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Protein expression and purification 
The expression and purification of HG2 and its mutants was conducted exactly as described 
previously [11].  Briefly, for the screening of HG2 mutants, 200 µL LB/ampicillin grown overnight 
at 37°C with shaking after inoculation from frozen BL-21 (DE3) E.coli stocks.  The full 200 µL of 
overnight culture was added to 5 mL of Overnight Express Instant TB media (Novagen) with 
ampicillin in 24-well culture plates (Whatman) with Bugstopper Venting Capmats (Whatman).  
Cultures were grown at 37°C with shaking, and then moved to 18°C with shaking to be grown 
overnight.  Cells were harvested by centrifugation at 5000 x g for 10 minutes at 4°C.  Each 100 mL 
pellet was resuspended in 8 mL of lysis buffer (50 mM sodium phosphate, pH 8.0, 0.3 M NaCl, 2.5 
mM imidazole, 1x CelLytic B (Sigma-Aldrich), 5 mM β-mercaptoethanol (βME), 0.2 mg/mL 
lysozyme (Sigma-Aldrich), and 1 U Benzonase endonuclease (Merck)).  The lysate was centrifuged 
at 19000 x g for 45 at 4°C and the supernatant collected. 
For full-scale purification, proteins were expressed in 1 L LB/ampicillin cultures in BL-21 (DE3) 
E.coli inoculated with 10 mL overnight starter cultures grown at 37°C.  The 1 L cultures were 
grown at 37°C until reaching OD600 ~ 0.6.  Expression was induced upon the addition of 1mM 
isopropyl β-D-1-thiogalactopyranoside (IPTG) and grown at 18°C for 18 hours.  Cells were 
harvested by centrifugation at 5000 x g for 10 min at 4°C.  The pellet was resuspended in 10 mL of 
equilibrium buffer (50 mM sodium phosphate with 0.3 M sodium chloride, pH 8.0), 1 U Benzonase, 
and both RNAse and Lysozyme and lysed by sonication (Misonix).  The lysed cells were 
centrifuged at 15,000 x g for 40 min at 4°C.  The supernatant was incubated at 4°C for 1 hour with 
2 mL of affinity gel suspension (HIS-select) (Sigma-Aldrich) that had been equilibrated with 10 bed 
volumes of equilibrium buffer (50 mM sodium phosphate with 0.3 M sodium chloride, pH 8.0).  
The resin was washed in a gravity column with 10 bed volumes of Wash I buffer (50 mM sodium 
phosphate with 0.3 M sodium chloride, pH 8.0, 10 mM imidazole), and then again with 10 bed 
volumes of Wash II buffer (50 mM sodium phosphate with 0.3 M sodium chloride, pH 8.0, 20 mM 
imidazole).  3 mL of elution buffer (50 mM sodium phosphate with 0.3 M sodium chloride and 250 
mM imidazole, pH 8.0) was then used to elute the protein.  The eluate was concentrated and buffer 
exchanged using a Amicon Ultra -15 filter 10,000 MWCO centrifugal concentrators into storage 
buffer (50 mM sodium citrate pH 5.5, 150 mM NaCl). 
 
Protein concentration determination 
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Protein concentrations were determined by UV absorbance denaturation in 8 M guanidinium 
hydrochloride for 5 minutes at a dilution of 10x to 100x.  The extinction coefficient for each protein 
at 280 nm was calculated based on the number of tryptophans and tyrosines in the protein using 
ExPASy’s ProtParam tool. 
 
Kemp elimination activity screening 
Cell lystates from the small scale purifications described above were used to screen for Kemp 
elimination by added 20 µL of lysate to 180 µL of assay buffer (25 mM HEPES, pH 7.25, 100 mM 
NaCl, and 0.8 mM 5-nitrobenzisoxazole (5-NBZ)).  Reactions were conducted in black 96-well 
microtiter plate with clear bottom (Greiner) and the production of the phenolate product was 
monitored by an increase in absorbance at 380 nm using a Safire2 microplate reader (Tecan).  All 
mutants’ activity were normalized to WT. 
 
Kinetic measurements 
Michaelis-Menten parameters were determined using 5 µM purified enzyme and monitoring 
phenolate production at 380 nm (ε = 15,800 cm-1M-1) [2] using a Shimadzu UV 1601 
spectrophotometer at 27°C.  Assays were conducted in assay buffer (25 mM HEPES, pH 7.25, 100 
mM NaCl, and 0.031 to 1 mM 5-nitrobenzisoxazole (5-NBZ)).  Initial rates were calculated from 
the first 300 sec of the reaction.  The rate of reaction versus the corresponding substrate 
concentration was fit to the Michaelis-Menten equation (equation 2), 
                                        v = Vmax[S]/Km + [S] (2) 
where v is the initial reaction rate, Vmax is the maximal rate of reaction, Km is the Michaelis constant, 
and [S] is the substrate concentration. 
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PHOENIX energy calculations 
PHOENIX energy calculations were conducted to score the mutants as was previously reported [7, 
11].  Briefly, calculations were conducted using single state design based on the HG2/S265T design 
structure using occlusion-based solvation and the optimization algorithm FASTER [12].  Residues 
16, 17, 46, 47, 50, 79, 87, 90, 170, 207, 209, 239, 275, and 276 were floated, allowing the WT 
sidechains to sample alternative conformations using a backbone independent library.  One design 
position was designated per calculation and allowed to mutate to every possible amino acid.  The 
calculations yielded a predicted structure file and a score for each mutant.   
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Results and Discussion 
Site-Directed Mutagenesis 
Mutagenesis reactions were initially intended to be carried out in 96-well PCR plates using Phusion 
HS polymerase (New England Biolabs) on the robot using the calculated heating setting on the 
thermocycler.  These first attempts failed, however, and conditions were optimized by hand to what 
is listed above (PfuTurbo DNA polymerase, etc.).  Additional experiments demonstrated that doing 
mutagenesis by hand using PCR tubes gave better results than running these reactions on the robot 
in PCR plates.  Running reactions by hand also allowed for more flexibility when certain reactions 
had to be repeated from previous 96-well plates, or when a second stage of PCR was required to 
generate amplified template.  Therefore, mutagenesis reactions were carried out by hand using PCR 
tubes.  Further optimizations are necessary to successfully complete these reactions using the 
automated site-directed mutagenesis method. 
 
HG2 Mutants 
In all, 206 of the original 209 mutants were obtained (98.6%).  Table 1 summarizes the number of 
mutants obtained for each culture plate.  In total, four sets of culture plates were used.  The average 
percent of mutants obtained from wells with colonies was 84.2%.  Of the third colonies picked from 
a well after the first two sequenced at Agencourt did not yield the desired result, 28% from plate 1 
and 50% of those from plate 2 were the correct sequence.   
Third colonies were picked only for the first and second plate.  The remaining mutants after three 
sets of plates were repeated from the mutagenesis step and sent on a fourth plate.  This yielded a 
high success rate: 88.0% of these mutants were obtained.  Based on these results, sending two 
colonies for sequencing appears to be optimal.  This may suggest that if the correct sequence is not 
obtained within the first two colonies sequenced, the mutagenesis reaction has something inherently 
wrong with it. 
The third plate was the most troublesome; only 63.3% of the mutants with colonies were correct, 
and the overall transformation was very poor.  Two issues may have contributed to this: (1) 49 of 
the 88 reactions were mutants that had failed on previous plates, and (2) the amount of cells ran out 
during transformation, leaving some wells with very little competent bacteria.  The failed reactions 
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were repeated using the two-round method of PCR, and gave much better results.  Use of the two-
round method for mutants that had trouble forming amplified template was generally helpful. 
The mutagenesis reactions and transformations were repeated for the remaining three mutants of the 
original 209 (A21D, M84G, and M237S) until they were obtained. 
 
Kemp elimination activity screening and kinetic characterization 
Of the 209 mutants screened, 22 were exhibited higher activity than WT protein (Figure A-4).  Six 
of the 22 mutations were also found to increase HG2/S265T activity in screens in the Hilvert lab, 
which used directed evolution to discover mutations that could improve the enzymes activity [13].  
Since this was a screen using cell lysates, uncorrected for expression levels, 21 of these mutants 
were purified and kinetically characterized.  Of those initial 22 mutants, 21 plus WT (HG2/S265T), 
scaffold (1GOR), and knockout D127V were purified and assayed.  Of these 21 point mutants, four 
were found to be more active than HG2/S265T: K50M, M172I, M84I, and K50Q (Table A-2).  
Only one of these mutations, K50M, was used in HG3.17, the most active HG2/S265T evolved 
mutant found by the Hilvert lab [13].   
The contradictory results between the screen and the assays are probably due to differential levels of 
expression between HG2/S265T and the mutants.   
 
PHOENIX characterization of active site saturation mutants 
The overall energy score for each mutant was relatively well anti-correlated to the kcat/Km value 
(Figure A-5).  However, as expected, HG2/S265T was scored as the most stable of the sequences. 
Indicating that our method for predicting which sequence would best catalyze the Kemp elimination 
is definitely flawed.  This is due to probably several factors, a few of which being: (a) inaccuracies 
the force field itself, (b) the scoring is based on a static picture of the enzyme and movement may 
play a part in catalysis, (c) inaccuracies or fundamentally flawed method for how we define the 
stabilization of the transition state, and especially (d) the recent finding that the substrate is flipped 
in the HG3.17 structure, indicating that for many of these mutants the orientation of the substrate 
may be defined incorrectly [13]. 
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The flipped orientation of the substrate is very relevant, considering that the above authors found 
that in this configuration, K50Q assumes the designed role of S265T, and donates a hydrogen bond 
to the phenoxide leaving group [13].  This flipping of the substrate also makes it difficult to predict 
how the other beneficial mutations are enhancing the catalysis.  Therefore, redoing the calculations 
in the newer program TRIAD with the new orientation of the substrate may yield a better anti-
correlation between activity and energy score. 
Multi-state design (MSD) and molecular dynamics have also been used to better model movement 
in catalysis and protein function [7, 14].  These techniques could also be used to improve our ability 
to predict which mutations would result in the best catalyst. 
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Conclusions 
Designing the de novo Kemp elimination enzyme, HG2/S265T, with a kcat/Km of 430 M−1s−1 is 
already an incredible accomplishment.  HG3.17 has a kcat/Km of 2.3 x 105 [13].  In this study, we 
were able to improve the kcat/Km of 2.5 x 103 using only computational design and active site 
saturation mutagenesis.  Further studies should test the activities of mutants containing a 
combination of the most active mutants.  However, the rate enhancement and efficiency of 
HG2/S265T, HG2/S265T/K50M, and HG3.17 does not approach those seen in natural enzymes 
(which typically have kcat/Km values in the neighborhood of 107 M−1s−1 [15]).  The upper limit of 
kcat/Km imposed by the diffusion-controlled limit is 108 to 109 M−1s−1 [1].  Ideally, we would like to 
be able to design enzymes with kcat/Km values close to these, but clearly our current design 
technique needs to be further optimized to achieve such a goal.  These 209 mutants will hopefully 
not only allow us to improve the activity of HG2/S265T, but also identify weaknesses in both our 
already moderately successful PHOENIX and MD design protocols.  Optimizing parameters so that 
predictions match what is observed will improve our models’ accuracy, allowing us to design better 
enzymes. 
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Figures and Tables 
 
Figure A-1.  The Kemp elimination of 5-nitrobenzisoxazole.  A base abstracts a proton from the C3 
position of 5-nitrobenzisoxazole to yield 2-cyano-4-nitrophenolate. 
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Figure A-2.  Design structure of HG2.  (A) shows the transition state, NBX (magenta), placed in the 
design active site of HG−2 within the structure of the scaffold, TAX.  (B) shows the active site 
design of HG−2 with NBX surrounded by Ser265, Trp44, Lys50, and the catalytic residue Asp127. 
 
Ser265 
Lys50 
Asp127 
Trp44 A 
B 
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Figure A-3a.  HG-2 active site residues chosen for site-saturation mutagenesis 
Images are from the design structure of HG−2.  Residues for mutagenesis are shown in purple, and the transition state, NBX is shown in magenta.  Trp44 π_stacks with NBX 
and Lys50 interacts with NBX’s nitro group. 
Lys50 Met84 
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Figure A-3b.  HG-2 active site residues chosen for site-saturation mutagenesis, continued 
Images are from the design structure of HG-2.  Residues for mutagenesis are shown in purple, and the transition state, NBX, is shown in magenta.  Asp127 is the catalytic 
base.  Ser265 was meant to hydrogen bond with the isoxazole oxygen (Thr265 in HG-2 S265T). 
 
Asp127
Met172 Met237
Leu236 
Ser265	  (Thr265) 
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  Table A-1.  Summary of site-saturation mutagenesis results 
 
Plate 
Total # 
Rxns 
# of Rxns w/ 
Colonies 
# Mutants Achieved 
After Agencourt 
Seq. 
# Mutants 
Achieved After 
3rd Seq. 
 
 
 
% Mutants 
Achieved After 
Agencourt Seq. 
% Mutants 
From 
Colonies 
% Mutants 
Achieved 
From Total 
Rxns 
1 95 92 67 74 72.8 80.4 77.9 
2 76 76 72 74 94.7 97.4 97.4 
3 88 60 38 N/A 63.3 63.3 43.2 
4 25 23 22 N/A 95.7 95.7 88.0 
AVG     81.6 84.2 76.6 
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                                       Figure A-4.  Activity screen of site saturation mutants for HG2/S265T.  Mutations also found by Hilvert lab in red. 
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                                            Table A-2.  Kinetic data for the HG2/S265T mutants found in the screen to be more active than “WT.” 
 
Mutant 
Normalized 
Scrren 
Activity Vmax (M/s) kcat (s-1) Km (M) kcat/Km (s-1M-1) 
K50M 4.24 1.79E-05 ± 1.86E-06 3.58E+00 ± 3.71E-01 1.45E-03 ± 2.24E-04 2.47E+03 ± 4.60E+02 
M172I 2.86 2.99E-05 ± 6.27E-06 5.99E+00 ± 1.25E+00 2.84E-03 ± 7.58E-04 2.11E+03 ± 7.17E+02 
M84I 1.33 1.45E-05 ± 1.67E-06 2.90E+00 ± 3.35E-01 1.58E-03 ± 2.66E-04 1.84E+03 ± 3.75E+02 
K50Q 1.70 1.87E-05 ± 2.78E-06 3.74E+00 ± 5.56E-01 2.30E-03 ± 4.55E-04 1.63E+03 ± 4.03E+02 
HG2 S265T 1 1.30E-05 ± 2.48E-06 2.59E+00 ± 4.97E-01 2.90E-03 ± 7.06E-04 8.93E+02 ± 2.77E+02 
M172C 1.67 1.59E-05 ± 1.04E-05 3.17E+00 ± 2.07E+00 4.40E-03 ± 3.40E-03 7.21E+02 ± 7.30E+02 
K50H 1.68 8.76E-06 ± 1.47E-06 1.75E+00 ± 2.95E-01 2.66E-03 ± 5.78E-04 6.59E+02 ± 1.81E+02 
M172L 1.35 1.76E-05 ± 5.90E-06 3.52E+00 ± 1.18E+00 6.00E-03 ± 2.29E-03 5.86E+02 ± 2.98E+02 
M172V 1.18 4.79E-06 ± 8.63E-07 9.57E-01 ± 1.73E-01 2.36E-03 ± 5.64E-04 4.05E+02 ± 1.21E+02 
M172T 1.44 2.82E-06 ± 2.73E-07 5.63E-01 ± 5.47E-02 1.41E-03 ± 2.06E-04 4.00E+02 ± 7.03E+01 
M84L 1.29 5.63E-06 ± 2.88E-06 1.13E+00 ± 5.75E-01 3.21E-03 ± 2.04E-03 3.51E+02 ± 2.86E+02 
L236M 1.06 3.25E-06 ± 6.20E-07 6.50E-01 ± 1.24E-01 2.49E-03 ± 6.21E-04 2.61E+02 ± 8.21E+01 
M237C 1.12 3.67E-06 ± 8.40E-07 7.33E-01 ± 1.68E-01 3.10E-03 ± 8.90E-04 2.37E+02 ± 8.70E+01 
M84C 1.19 2.61E-05 ± 4.78E-05 5.23E+00 ± 9.56E+00 2.46E-02 ± 4.66E-02 2.12E+02 ± 5.58E+02 
L236D 1.42 4.13E-07 ± 4.17E-08 8.26E-02 ± 8.33E-03 5.78E-04 ± 1.15E-04 1.43E+02 ± 3.20E+01 
W44Y 1.47 2.55E-05 ± 5.47E-05 5.10E+00 ± 1.09E+01 3.65E-02 ± 8.03E-02 1.39E+02 ± 4.28E+02 
M84V 1.07 9.02E-07 ± 1.20E-07 1.80E-01 ± 2.39E-02 1.55E-03 ± 3.02E-04 1.16E+02 ± 2.73E+01 
K50F 2.08 2.42E-06 ± 6.08E-07 4.85E-01 ± 1.22E-01 4.42E-03 ± 1.31E-03 1.10E+02 ± 4.26E+01 
L236V 1.03 9.60E-07 ± 2.07E-07 1.92E-01 ± 4.14E-02 3.27E-03 ± 8.76E-04 5.88E+01 ± 2.02E+01 
M84P 1.01 1.33E-07 ± 8.11E-09 2.65E-02 ± 1.62E-03 4.73E-04 ± 6.12E-05 5.60E+01 ± 8.02E+00 
L236Q 1.12 2.91E-07 ± 7.58E-08 5.82E-02 ± 1.52E-02 2.10E-03 ± 7.43E-04 2.78E+01 ± 1.22E+01 
1GOR N/A 8.90E-08 ± 4.41E-08 1.78E-02 ± 8.81E-03 3.20E-03 ± 1.97E-03 5.57E+00 ± 4.41E+00 
D127V 0.82 8.84E-09 ± 1.83E-09 1.77E-03 ± 3.65E-04 3.60E-04 ± 1.72E-04 4.91E+00 ± 2.55E+00 
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Figure A-5.  Calculated PHOENIX energy (black) versus kcat/Km (blue) of the HG2/S265T active 
site saturation mutants. 
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A p p e n d i x  B  
EXPLORING CYANOVIRIN BINDING TO EBOLA GLYCOPROTEIN 1,2 TO FACILITATE 
FUTURE ANTIVIRIAL DESIGNS 
Abstract 
Many deadly diseases are caused by enveloped viruses, including AIDS, smallpox, hantavirus 
disease, and Ebola.  New fears of viral breakouts due to bioterrorism or increased international 
travel have made the development of broad-spectrum antivirals a medical priority.  Cynaovirin-N 
(CVN) is a lectin with potent antiviral activity against many enveloped viruses.  CVN binds high-
mannose glycosylation sites on viral envelope glycoproteins, blocking their ability to effectively 
bind to host cell receptors and initiate membrane fusion, thus preventing infection.  Ebola 
glycoprotein 1,2 (GP1,2) is the viral envelope protein on Ebola virus (a biohazard level 4 pathogen) 
that initiates membrane fusion.  The mucin-like domain of GP1,2 is the primary viral determinant of 
Ebola pathogenicity.  CVN exhibits antiviral activity against Ebola, and it has been shown that such 
activity most likely originates from CVN’s ability to bind GP1,2.  Our goal is to design CVN 
variants with improved antiviral activity that could potentially be used as broad-spectrum antiviral 
therapeutics.  Toward this goal, we plan to develop in vitro CVN binding assays to a wide range of 
viral envelope glycoproteins, thereby providing a safe way to estimate the antiviral activities of the 
variants. Thus far, we have expressed GP1,2 with the mucin-like domain in insect cells.  Future 
work will include the development and optimization of other GP1,2-CVN assays as well as assays 
involving other viral envelope glycoproteins. 
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Introduction 
Enveloped Viruses 
A virus is an infectious agent and intracellular parasite, and often causes disease in its animal host.  
Viruses are unable to reproduce themselves, and therefore must infect a host cell and commandeer 
its molecular machinery in order to replicate.  An infectious virus particle, or virion, consists of 
nucleic acids making up the viral genome, a surrounding protein capsid, and in some cases, an outer 
phospholipid bilayer envelope.  Viruses with these outer membranes are known as enveloped 
viruses.  During replication of an enveloped virus, the capsid assembles around the viral genome 
and buds from the host cell.  During budding, part of the host cell membrane coats the protein, 
becoming the viral envelope.  Within the envelope are heavily glycosylated virus-encoded proteins, 
which bind to host cell membrane receptors, facilitating the membrane fusion event that occurs 
when the newly-budded virus infects another host cell.  These glycoproteins are known as fusion 
proteins, and their heavy glycosylation acts to cloak them from normal immune system responses 
[1]. 
 
Ebola Virus 
Enveloped viruses cause a myriad of human diseases, such as AIDS (acquired immunodeficiency 
syndrome), influenza, small pox, herpes simplex, SARS (severe acute respiratory syndrome), and 
Ebola [2, 3].  Ebola virus (EBOV) is a member of the Filovirdae family and causes hemorrhagic 
fever with mortality rates of 50-90% [2].  Five species of the virus exist: Bundibugyo, Sudan, Côte 
d’Ivoire, Reston, and Zaire.  Ebola Zaire is the most lethal of these, with mortality rates of 90% [4].  
Patients infected with Ebola exhibit headache, nausea, malaise, high fevers, aberrant coagulation 
and vascular permeability causing bleeding, bruising and rashes [5].  Death results from multiple 
organ failure within 6-9 days after the first appearance of symptoms [6]. 
Ebola patients mainly receive palliative care [5].  Several preliminary vaccine trials in primates 
have been successful [7-10], but no approved vaccines, post-exposure treatments or cures for 
humans exist [5].  Ebola outbreaks have increased more than four-fold since 1994, and Ebola has 
been identified as a virus that may be used as a biological weapon [11].  Therefore, the development 
of vaccines and therapies for Ebola has become a high priority.   
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Cyanovirin-N 
Cyanovirin-N (CVN) is an 11 kDa lectin exhibiting potent antiviral activity against many enveloped 
viruses, and is a promising candidate for broad-spectrum antiviral therapy [12, 13].  CVN was 
isolated from the cyanobacterium Nostoc ellipsosporum in a screen conducted to find compounds 
with anti-human immunodeficiency virus (HIV) activity [13].  In addition to being a potent antiviral 
against HIV [13-16], CVN has been shown to have activity against influenza [17, 18], hepatitis C 
[19], herpesvirus 6, measles [20], and Ebola [12, 21].  In each of these cases, CVN binds high-
mannose glycosylation sites on the viral envelope glycoproteins, blocking their ability to effectively 
bind to host cell receptors and initiate membrane fusion, thus preventing infection.     
CVN has two binding sites, a “high affinity” and “low affinity” site (Figure B-1) [22], and 
specifically binds α(1-2) linked oligomannose moieties within Man-8 or Man-9 glycosylation sites 
[22-25].  Such high mannose glycosylation is often found on viral envelope proteins, but is 
uncommon in mammalian oligosaccharides. This may allow CVN to specifically target viruses and 
infected host cells rather than healthy host tissue, an important characteristic for a potential 
therapeutic.  CVN is small and stable [13, 26-28].  In non-human primate studies, CVN has already 
been shown to be an effective prophylactic against rectal and vaginal SIV/HIV-1 transmission, 
exhibiting only a low level of toxicity [14, 15]. Treatment with CVN can also cause HIV and 
influenza to evolve to eliminate N-linked glycosylation sites on their envelope glycoproteins [16, 
17, 29, 30].  However, loss of glycosylation exposes the protein to the adaptive immune system, and 
has been shown to make such viruses more susceptible to antibody neutralization [31].  Such 
characteristics make CVN a potentially very valuable drug. 
 
Ebola Glycoprotein 1,2 
The Ebola virus genome contains 7 genes from which 8 proteins are synthesized.  The GP gene 
directs the synthesis of two proteins via a transcriptional editing event: sGP and GP1,2.  sGP, a 364-
residue secreted glycoprotein whose function remains unclear, is the primary gene product.  The 
synthesis of the secondary protein, GP1,2, occurs upon addition of a non-templated adenosine 
within a length of 7 adenosines in the coding region [32, 33].  GP1,2 is a 676-residue 
transmembrane-linked glycoprotein that is post-translationally cleaved by furin into the subunits 
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GP1 and GP2.  These subunits remain covalently linked via a single disulphide-bond [34].  GP1 
serves as the viral envelope protein that causes viral attachment to host cells, whereas GP2 mediates 
virus-host membrane fusion [35-37].  GP1,2  assumes a trimeric complex on the envelope (Figure 
B-2).   
In addition to its role in membrane fusion, GP1,2 synthesis has also been shown to be the main 
determinant of Ebola pathogenicity [38-42].  Specifically, this cytotoxicity was mapped to the 
heavily glycosylated mucin-like domain of GP1,2.  Synthesis of Zaire GP1,2 in human embryonic 
kidney 293 cells caused cell rounding and detachment within 24 hours after transfection, and 
eventually resulted in cell death, whereas the expression of sGP and GP1,2(Δmuc), a GP1,2 mutant 
with a deletion of the mucin-like domain, caused no such effects.  Addition of cycloheximide (a 
protein synthesis inhibitor) to cells expressing GP1,2 blocked the cytotoxicity.  Expression of Zaire 
GP1,2 in human saphenous vein explants resulted in the erosion of the endothelial cell layer and 
exposure of the underlying basement membrane.  These explant experiments were repeated in 
human and cynomolgus monkey vessels using the GP1,2 from Ebola Reston, which is highly lethal 
in many primates, but not humans.  While the monkey vessels showed similar damage to those 
human vessels expressing Zaire GP1,2, the human vessels expressing Reston GP1,2 remained 
unaffected [38]. 
For these reasons, GP1,2 is the main target for vaccine and antiviral therapy design.  Moreover, it 
has been shown that CVN binds to GP1,2, and this binding is the probable mechanism providing 
CVN with its anti-Ebola activity [21].     
A goal of our lab is to engineer a CVN variant with increased antiviral activity that could be used as 
a broad-spectrum antiviral therapeutic or prophylactic.  Several variants with improved antiviral 
activity have been constructed, and work on a “lectibody” (a CVN-Fc variant designed to induce an 
immune response) is underway [43]. So far, testing of these CVN variants has been limited to HIV 
and influenza systems.  We would like to expand to other viral models.  However, due to their level 
4 biohazard rating, it is impossible for us to work with small pox virus and Ebola virus in our 
facilities.  In collaboration with Irene Maier, a postdoc in our lab, I am instead developing in vitro 
CVN binding assays with Ebola GP1,2, which will provide a safe way to estimate the antiviral 
activity of our designed variants.  Data from these assays will then be used to improve upon existing 
designs to create a therapeutic CVN variant with superior avidity that retains its broad-spectrum 
capabilities.  
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Methods 
Construct Design 
The sequence for Ebola Zaire GP1,2 was obtained from the NCBI (National Center for 
Biotechnology) database.  Recombinant Ebola Zaire GP1,2 gene was designed to include residues 
33 through 632, excluding residues 1-32 (the signal peptide) and 633-676 (the membrane-proximal 
external region, the transmembrane region and the cytoplasmic tail).  An N-terminal His-6 tag, TEV 
cleavage site and GGSGG-linker were added to the N-terminus of the protein (Figure B-3).  A 
single adenosine was added to the 7-long adenosine span in the gene sequence to ensure the 
synthesis of GP1,2 over sGP. 
Gene Assembly and Cloning 
40-nucleotide long overlapping oligonucleotides were used to construct the GP1,2 gene. We 
employed the recursive PCR (polymerase chain reaction) method as described in Stemmer et al. 
[44], except the assembly reaction was divided into three stages: (1) an initial stage in which the 
gene was divided into quarters and each quarter was assembled individually, (2) a repeat assembly 
on each quarter in which the reaction was spiked with dNTPs and polymerase, and (3) a final stage 
in which the 4 previously assembled quarters were combined and assembled into the full-length 
gene (Figure B-4).  The assembled gene was subsequently cloned into baculovirus transfer vector 
pAcGP67A (BD Biosciences). 
 
Protein Expression and Purification 
All recombinant baculovirus generation, protein expression, and protein purification was performed 
at the Protein Expression Center (Caltech).  Recombinant baculoviruses were generated using 
purified pAcGP67A with the Ebola Zaire GP1,2 gene insert in Spodoptera frugiperda (Sf9) insect 
cells.  Protein was expressed in 1 L Sf9 cultures infected with recombinant baculovirus. Protein was 
purified via Ni-NTA affinity chromatography and was stored in 10 mM sodium phosphate, 140 mM 
sodium chloride at pH 7.4. 
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Verification of Cleavage Event to Form GP1 and GP2 
Sodium dodecyl sulfate polyacrylamide gel electrophoresis (SDS-PAGE) and liquid 
chromatography-mass spectrometry (LC-MS) were both run on reduced and unreduced samples of 
purified GP1,2 to determine if the cleavage event that separates the protein into GP1 and GP2 
occurred.  LC-MS was conducted at the Protein/Peptide MicroAnalytical Laboratory (Caltech).  An 
in-gel trypsin digestion with reduction and alkylation of Coomassie stained bands followed by 
analysis by mass spectrometry was also conducted on purified GP1,2 at the Proteome Exploration 
Laboratory (Caltech). 
 
Circular Dichroism (CD) 
CD data were obtained using an Aviv DS spectropolarimeter and the temperature was controlled 
with a thermoelectric unit.  Samples contained 3.7 µM protein in buffer containing 2.5 mM sodium 
phosphate and 35 mM sodium chloride at pH 7.4.  Wavelength scans were performed in triplicate in 
1 nm steps from 250 nm to 200 nm with an averaging time of 3 s. 
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Results and Discussion 
Gene Assembly and Expression 
Gene assembly yielded an expected PCR product of 1.8 kilobases.  The method of dividing the gene 
assembly oligonucleotides into sets of quarters and running an initial assembly reaction on each 
yielded much better results than performing an equivalent number of assembly reactions while 
including all oligonucleotides (Figure B-5).  These results demonstrated that smaller gene pieces 
assembled better, whereas running more assembly reactions helped minimally. 
To avoid deletion of the mucin domain, which is necessary for expression in human cells, yet retain 
glycosylation, an insect cell line was chosen for Ebola GP1,2 expression as previously described 
[45, 46].  1 L cultures yielded about 8 mg of soluble protein (Figure B-6). 
 
Verification of Cleavage Into GP1 and GP2 
Because GP1 and GP2 are linked only by a single disulfide bond, SDS PAGE with reducing 
conditions should yield two separate bands.  The molecular weight of unglycosylated GP1,2 is 
expected to be 67.737 kilodaltons (kDa), with GP1 at 53.075 kDa., and GP2 at 14.662 kDa.  
Reduced GP1,2 SDS PAGE showed a shift of on the order of 12 kDa down from its corresponding 
position on the gel in its unreduced form (Figure B-7).  In addition, bands appear around 21 kDa 
when GP1,2 is run under reduced conditions.  
LC-MS was also done on reduced and unreduced samples of GP1,2.  Under unreduced conditions, 
two species were observed: one at 70.834 kDa and one at 71.550 kDa (Figures B-8 and B-9).  The 
molecular weight of mannose is 180.156 Daltons (Da).  The difference in weight between the two 
species is 716 Da (equivalent to ~ 4 mannoses).  These two species may represent two forms of 
GP1,2 with slightly different glycosylation.  The reduced sample yielded three species: one with a 
small peak and a molecular weight of 70.846 kDa, a species at 14.663 kDa, and a third at 24.264 
kDa (Figures B-10, B-11, and B-12). 
The 14.663 kDa peptide corresponds to GP2, which has a predicted molecular weight of 14.662 
kDa.  The peptide with a weight of 70.846 kDa probably corresponds to the full-length GP1,2, as 
observed under unreduced conditions.  The second species of full-length GP1,2 (71.550 kDa) does 
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not appear under reduced conditions.  The third species at 24.264 kDa in reduced conditions 
appears to be a fragment of GP1.  Perhaps full-length GP1 has trouble flying during mass 
spectrometry and therefore remains undetected. 
To further investigate this, a trypsin digestion followed by mass spectrometry was also conducted, 
but unfortunately the protein prep used for this experiment was unusually unstable and had 
degraded, yielding a reduced gel with many bands, making the results inconclusive.  However, 
several bands were still analyzed, and large coverage of the peptide sequence was found, leading 
one to believe that the entire GP1,2 was being expressed.     
 
CD Analysis of GP1,2 
CD analysis of GP1,2 (Figure B-13) showed that the protein exhibits both α- and β-secondary 
structural elements, which is in agreement with the published crystal structure (Figure B-14).  
Proteins with both α- and β-secondary structure often show two negative CD bands at 222 and 208-
210 nm and one positive band near 190-195 nm similar to those of all-α proteins.  Sometimes a 
single, broad minimum may appear between 210 and 220 nm due to overlapping of various α-helix 
and β-sheet bands [47].  GP1,2 exhibited a negative band at about 207 nm with a broad shoulder at 
~220 nm.  
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Future Work 
Structure of GP1,2 
To further support that GP1,2 is correctly folded, CD will be used to monitor a thermal denaturation 
of the protein.  If the protein is folded, it should be possible to determine the melting temperature of 
the protein by observing the loss of current secondary structure. 
Future work will also include attempting to crystallize our Ebola GP1,2 construct.  The current 
crystal structure of GP1,2 was obtained from a construct without the mucin-like domain [11].  
Solving a crystal structure of our recombinant GP1,2 would not only definitively verify whether or 
not the protein was folded correctly, it would also provide the first atomic resolution structure of the 
toxic mucin-like domain.   
Repeating the trypsin digestion and mass spectrometry on a new batch of GP1,2 will also be done to 
identify the bands obtained when running SDS-PAGE on reduced and unreduced samples of GP1,2.  
This experiment will confirm whether or not the protein has been processed correctly.  If it has not, 
the enzyme furin (New England Biolabs) will be used to cleave GP1,2 after expression and 
purification. 
 
Generation of an Unglycosylated GP1,2  
To crystallize our GP1,2 protein and to generate a negative control for our CVN binding studies, we 
will attempt to fully deglycosylate GP1,2.  The current crystal structure of GP1,2 was obtained after 
deglycosylation of GP1,2 by the enzyme PNGase F [11]. PNGase F removes N-linked 
glycosylation from proteins and is often used for this purpose on proteins intended for 
crystallization screens to help increase sample homogeneity and promote crystal contacts.  
However, the serine- and threonine-rich mucin-like domain contains many predicted regions of O-
linked glycosylation.  Indeed, incubating our GP1,2 with PNGase F results in a smear on an SDS-
PAGE gel.  There is no enzyme comparable to PNGase F for the removal of O-linked 
glycosylation, so another strategy will have to be used.  Unfortunately, expression of GP1,2 in E. 
coli to avoid glycosylation has previously been shown to be impossible [42]. One option is to 
construct another mutant of GP1,2 with the mucin-like domain deleted.  This construct would only 
be useful as a negative control for binding studies.  To get a crystal structure of the mucin-like 
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domain, one possible option is to mutate out all the predicted sites of O-linked glycosylation.  
Unfortunately, the mucin-like domain, which spans 151 residues, includes 21 serines and 27 
threonines, so such a tactic might not be feasible.   
 
Optimizing Storage Buffer Conditions 
The batches of GP1,2 from our expression system have proven somewhat unstable.  We store the 
protein at 4°C in 10 mM sodium phosphate and 140 mM sodium chloride at pH 7.4.  Two 
expressions have been done; the first broke down after approximately two months under these 
conditions, and the second degraded within three weeks.  Flash freezing the protein stops 
degradation, but upon thawing the protein breaks down within a few days.  To avoid this, storage 
buffer conditions need to be optimized.   
 
TEV Cleavage and ELISA 
We plan to investigate GP1,2 binding to CVN using enzyme-linked immunosorbent assays 
(ELISA).  In these experiments, GP1,2’s His-tag will be cleaved off, and the protein will be 
immobilized.  CVN will then be allowed to bind to GP1,2.  A primary antibody will then bind the 
His-tag of CVN.  The secondary antibody, which will be conjugated to horseradish peroxidase, will 
then bind the primary antibody, providing a mechanism for readout.  Such an assay will further 
characterize the binding of CVN and subsequent designed variants to GP1,2.  These data will then 
be used to improve the design of CVN antivirals.     
 
New Viral Proteins and CVN Engineering 
The ultimate goal of this project is to engineer a CVN variant that can be used as a broad spectrum 
antiviral.  These BIAcore and ELISA assays developed using GP1,2 will be used to characterize the 
binding ability of CVN in conjunction with binding and neutralization studies using HIV and 
influenza glycoproteins.  In addition to these glycoproteins, we wish to expand our binding assays 
to glycoproteins from other viruses that could become a threat, such as smallpox and hantavirus.  
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Having a wide range of assays with which to test our CVN variants will expand our ability to 
engineer as universal an antiviral as possible. 
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Figures 
 
Figure B-1.  WT CVN monomer bound to mannose moieties [48].  Carbohydrates in green are 
bound to the low affinity binding site, and those in magenta are bound to the high affinity site. CVN 
monomer is shown in purple. 
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Figure B-2.  Structure of Ebola glycoprotein GP1,2 [11].  (Left) Ebola GP1,2 consists of two peptides, GP1 and GP2, joined together by a single 
disulphide bond. GP1 is shown in purple and GP2 in silver. (Right) GP1,2 exists as a trimer on the surface of the viral envelope. 
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Figure B-3.  Gene construct and domains of Ebola Zaire GP1,2.  From left to right: dark red His, N-terminal His-tag; peach TEV+link, TEV cleavage 
site and GGSGG-linker; green I, GP1 base; purple II, GP1 head; cyan III, GP1 glycan cap; white Mucin, mucin-like domain; orange IFL, internal 
fusion loop; yellow HR1, heptad repeat 1; gold HR2, heptad repeat 2; light green MPER, membrane-proximal external region; light green TM, 
transmembrane domain.  All domain shown in light green (residues 633-676) were deleted from the gene.  The red Y’s indicate N-linked 
glycosylation sites (Adapted from Figure 1 of Lee et al. [11]). 
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Figure B-4.   Gene assembly protocol scheme.  Oligonucleotides are represented by rectangular boxes and are divided into four quarters or sets by 
color.  An initial assembly reaction was run on each set individually (round 1) and repeated (round 2).  The individual assemblies were then combined 
for a final assembly reaction (round 3), and then the final, full-length assembly product was amplified. 
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Figure B-5.  Gene assembly of GP1,2.  Dividing the assembly reaction into 4 subsets to run 2 initial 
assembly reactions, and then mixing these assembled quarters together for a final assembly yielded 
much better results than running all assemblies with all oligonucleotides present.  Agarose gel lanes 
contain as follows: lane 1: NEB 2-log ladder; lanes 2 and 3: amplification of PCR product where all 
sets (1-4) were together for all 3 rounds of gene assembly (initial assembly, repeated assembly, and 
final assembly); lanes 4 and 5: amplification of PCR products where sets 1-4 were separate for the 
first 2 rounds of assembly, and together on the final round. 
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Figure B-6.  GP1,2 purified from Sf9 cells.  Reduced SDS page gel run by Inderjit Nangiana at the 
Protein Expression Center shows purified GP1,2 running at approximately 95 kilodaltons in lane 2. 
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Figure B-7.  SDS-PAGE gels of Ebola Zaire GP1,2 under reduced and unreduced conditions.  Ebola 
GP1,2 shifts down the gel about 10 kDa as determined by graphing the logs of the distances 
traveled of each band versus its molecular weight.  Bands appear around 21 kDa under reduced 
conditions.  (A) was obtained running 50 µg of GP1,2, whereas in (B), 20 µg was run. 
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Figure B-8.  Liquid chromatography and time of flight mass spectrometry (TOF-MS) of unreduced 
GP1,2, species 1.  (A) The elution profile of a LC of the unreduced sample of GP1,2.  (B) The 
multiply-charged ion spectrum of the sample peak highlighted in A analyzed with TOF-MS.  (C) 
The multiply-charged ion peaks in B were reconstructed to yield a single peak with mass value of 
70.833 kDa. 
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Figure B-9.  Liquid chromatography and time of flight mass spectrometry of unreduced GP1,2, 
species 2.  (A) The elution profile of a LC of the unreduced sample of GP1,2.  (B) The multiply-
charged ion spectrum of the sample peak highlighted in A analyzed with TOF-MS.  (C)  The 
multiply-charged ion peaks in B were reconstructed to yield a single peak with mass value of 
71.550 kDa. 
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Figure B-10.  Liquid chromatography and time of flight mass spectrometry of reduced GP1,2, 
species 1.  (A) The elution profile of a LC of the reduced sample of GP1,2.  (B) The multiply-
charged ion spectrum of the sample peak highlighted in A analyzed with TOF-MS.  (C)  The 
multiply-charged ion peaks in B were reconstructed to yield a single peak with mass value of 
70.846 kDa. 
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Figure B-11.  Liquid chromatography and time of flight mass spectrometry of reduced GP1,2, 
species 2.  (A) The elution profile of a LC of the reduced sample of GP1,2.  (B) The multiply-
charged ion spectrum of the sample peak highlighted in A analyzed with TOF-MS.  (C)  The 
multiply-charged ion peaks in B were reconstructed to yield a single peak with mass value of 
14.663 kDa. 
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Figure B-12.  Liquid chromatography and time of flight mass spectrometry of reduced GP1,2, 
species 3.  (A) The elution profile of a LC of the reduced sample of GP1,2.  (B) The multiply-
charged ion spectrum of the sample peak highlighted in A analyzed with TOF-MS.  (C)  The mass 
of this peak was determined to be 24.264 kDa. 
 
 
 
 
 
 
 
A 
 
 
 
 
B 
 
 
 
 
C 
 
  
175 
 
 
 
 
 
 
 
 
 
 
 
 
Figure B-13.  CD wavelength scan of GP1,2.  Samples contained 3.7 µM protein in buffer 
containing 2.5 mM sodium phosphate and 35 mM sodium chloride at pH 7.4. GP1,2 exhibited a 
negative band at about 207 nm with a broad shoulder at ~220 nm, consistent with a structure 
containing α- and β-secondary structure. 
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Figure B-14.  GP1,2 colored by secondary structure.  The crystal structure of GP1,2 [11] shows 
both α- (cyan) and β- (magenta) secondary structural elements overlapping, consistent with the 
obtained CD wavelength scan in Fig. 13. 
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